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1.1 WHAT IS ISOPHORONE? 
 
Isophorone is a clear liquid with a peppermint-like odor. It 
evaporates faster than water but slower than charcoal starter or paint 
thinner, and it will not mix completely with water. Isophorone is a manmade 
chemical for use commercially, but it has been found to occur 
naturally in cranberries. It is used as a solvent in some printing inks, 
paints, lacquers, and adhesives. Isophorone does not remain in the air very 
long, but can remain in water for possibly more than 20 days. The length of 
time that isophorone will remain in soil is not known, but it probably is 
about the same as the length of time it remains in water. More information 
can be found in Chapters 3 and 4. 
 
1.2 HOW MIGHT I BE EXPOSED TO ISOPHORONE? 
 
Exposure to isophorone may take place where you work or in very low 
concentrations at home. Because it is used in some inks, paints, lacquers, 
and adhesives, people who work with these products may be exposed to 
isophorone. Isophorone has been found in the drinking water of Cincinnati, 
Philadelphia, and New Orleans at amounts less than 10 parts of isophorone in 
1 billion parts of water (10 ppb). In one instance (a screen print shop), 
isophorone was found in amounts as high as 26 parts in 1 million parts of 
air (26 ppm), but the usual amounts in the workplace are much lower. At 
this time, isophorone has been found in at least 9 out of 1177 National 
Priorities List (NPL) hazardous waste sites in the United States. Exposure 
to isophorone at these sites may occur by touching contaminated soil, 
water, or sediment. For more information please read Chapter 5. 
 
1.3 HOW CAN ISOPHORONE ENTER AND LEAVE MY BODY? 
 
Isophorone can enter your body if you breathe its vapor, have skin 
contact with it, drink contaminated water, or eat contaminated food. If 
isophorone is present at a waste site near homes that use local wells as a 
source of water, the well water could be contaminated with isophorone. 
Experiments in animals show that after doses by mouth, isophorone enters 
easily and spreads to many organs of the body, but most of it leaves the 
body within 24 hours in the breath and in urine. Isophorone may enter the 
lungs of workers exposed to isophorone where it is used indoors as a 
solvent. Isophorone disappears quickly from outside air, so the chance of 
breathing outdoor air contaminated with isophorone is small. If isophorone 
is spilled at a waste site and evaporates, however, a person nearby may 
breathe isophorone before it disappears from the air. In addition, soil 
around waste sites may contain isophorone, and a person, such as a child 
playing in the dirt, may eat or have skin contact with the contaminated 








More information on how isophorone can enter and leave-the body can be found 
in Chapter 2. 
 
1.4 HOW CAN ISOPHORONE AFFECT MY HEALTH? 
 
The only effects of isophorone reported in humans are irritation of the 
skin, eyes, nose, and throat, and possibly dizziness and fatigue. These 
effects have occurred in workers who breathe vapors of isophorone and other 
solvents during use in the printing industry. Short-term exposure of 
animals to high vapor amounts and short- or long-term exposure of animals to 
high doses by mouth cause death or a shortened lifespan. Short-term 
exposure to high amounts of vapors or high doses by mouth has caused 
inactivity and coma in animals. Inconclusive studies suggested that 
isophorone may have caused birth defects and growth retardation in the 
offspring of rats and mice that breathed the vapors during pregnancy. Some 
harmful health effects were seen in adult female animals in these studies. 
It is not known whether isophorone could cause birth defects in humans. In 
a long-term study in which rats and mice were given high doses of 
isophorone by mouth, the male rats developed kidney disease and kidney 
tumors. Male rats also developed tumors in a reproductive gland. Some male 
mice developed tumors in the liver, in connective tissue, and in lymph 
glands (tissues of the body that help fight disease), but the evidence was 
not strong. It is not known whether isophorone causes cancer in humans. 
More information on the health effects of isophorone in animals and humans 
can be found in Chapter 2. 
 
1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
ISOPHORONE? 
 
No medical test is known to determine human exposure to isophorone. A 
few studies in rats and rabbits have shown that isophorone and its 
metabolites can be found in the urine of these animals, so it may be 
possible to find a method for testing the urine of humans to determine 
exposure to isophorone. It is not known, however, whether such a 
measurement would predict how much exposure had occurred or the possible 
health effects. For more information see Chapter 2. 
 
1.6 WHAT LEVELS OF EXPOSURE HAVE RESULTED IN HARMFUL HEALTH EFFECTS? 
 
Tables l-l through l-4 show the link between exposure to isophorone and 
known health effects. A Minimal Risk Level (MRL) is also included in Table l-
3. This MRL was derived from animal data for long-term exposure, as 
described in Chapter 2 and in Table 2-2. The MRL provides a basis for 
comparison with levels that people might encounter in food. If a person is 
exposed to isophorone at an amount below the MRL, it is not expected that 
harmful (noncancer) health effects will occur. Because this level is based 
on information that is currently available, some uncertainty is always 
associated with it. Also, because the method for deriving MRLs does not use 












presence, absence, or level of risk of cancer. The information on health 
effects in humans or animals for short-term or long-term exposure to 
isophorone in air, for short-term exposure in food or water, and for longterm 
exposure in water was either not available or not suitable to derive 
MRLS. 
 
The amounts listed in Table l-l that cause eye, nose, and throat 
irritation (25 ppm) with short-term exposure and fatigue and depression (5 
ppm) with long-term exposure are much higher than the amount at which the 
odor is first noticed, which is about 0.2 ppm. This means that you can 
probably smell isophorone before you would have harmful health effects. The 
levels of isophorone in air that cause death and lung congestion in animals 
are much higher than the amounts that workers breathe in industry when using 
isophorone as a solvent. The amount that causes lung irritation in animals 
is about the same as the amount that causes eye, nose, and throat irritation 
in humans. 
 
Besides the harmful health effects from exposure to isophorone in air, 
food, and water, skin irritation or eye damage occurred in animals after a 
few drops of isophorone had been applied directly to the skin or eyes. 
 
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN 
HEALTH? 
 
The Environmental Protection Agency (EPA) has determined that the level 
of isophorone in natural waters (lakes, streams) should be limited to 5.2 
parts isophorone per million parts of water (5.2 ppm) to protect human 
health from the harmful effects of isophorone from drinking the water and 
from eating contaminated fish and other animals found in the water. The 
Occupational Safety and Health Administration (OSHA) has set a permissible 
exposure limit of 4 parts of isophorone per million parts of workroom air 
(4 ppm) during an 8-hour work shift to protect workers. The National 
Institute for Occupational Safety and Health (NIOSH) recommends that the 
amount in workroom air be limited to 4 ppm averaged over a 10-hour work 
shift. Further information on government recommendations can be found in 
Chapter 7. 
 
1.8 WHERE CAN I GET MORE INFORMATION? 
 
If you have more questions or concerns, please contact your State 
Health or Environmental Department or: 
 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology 
1600 Clifton Road, E-29 











This chapter contains descriptions and evaluations of studies and 
interpretation of data on the health effects associated with exposure to 
isophorone. Its purpose is to present levels of significant exposure for 
isophorone based on toxicological studies, epidemiological investigations, 
and environmental exposure data. This information is presented to provide 
public health officials, physicians, toxicologists, and other, interested 
individuals and groups with (1) an overall perspective of the toxicology of 
isophorone and (2) a depiction of significant exposure levels associated 
with various adverse health effects. 
 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
 
To help public health professionals address the needs of persons 
living or working near hazardous waste sites, the data in this section are 
organized first by route of exposure -- inhalation, oral, and dermal --and 
then by health effect -- death, systemic, immunological, neurological, 
developmental, reproductive, genotoxic, and carcinogenic effects. These 
data are discussed in terms of three exposure periods -- acute, 
intermediate, and chronic. 
 
Levels of significant exposure for each exposure route and duration 
(for which data exist) are presented in tables and illustrated in figures. 
The points in the figures showing no-observed-adverse-effect levels (NOAELs) 
or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses 
(levels of exposure) used in the studies. LOAELs have been classified into 
"less serious" or "serious" effects. These distinctions are intended to 
help the users of the document identify the levels of exposure at which 
adverse health effects start to appear, determine whether or not the 
intensity of the effects varies with dose and/or duration, and place into 
perspective the possible significance of these effects to human health. 
 
The significance of the exposure levels shown on the tables and graphs 
may differ depending on the user's perspective. For example, physicians 
concerned with the interpretation of clinical findings in exposed persons or 
with the identification of persons with the potential to develop such 
disease may be interested in levels of exposure associated with "serious 
effects." Public health officials and project managers concerned with 
response actions at Superfund sites may want information on levels of 
exposure associated with more subtle effects in humans or animals (LOAEL) or 
exposure levels below which no adverse effects (NOAEL) have been observed. 
Estimates of levels posing minimal risk to humans (minimal risk levels, 








For certain chemicals, levels of exposure associated with carcinogenic 
effects may be indicated in the figures. These levels reflect the actual 
doses associated with the tumor incidences reported in the studies cited. 
Because cancer effects could occur at lower exposure levels, the figures 
also show estimated excess risks, ranging from a risk of one in 10,000 to 
one in 10,000,000 (10-4 to 10-7), as developed by EPA. 
 
Estimates of exposure levels posing minimal risk to humans (MRLs) have 
been made, where data were believed reliable, for the most sensitive 
noncancer end point for each exposure duration. MRLs include adjustments to 
reflect human variability and, where appropriate, the uncertainty of 
extrapolating from laboratory animal data to humans. Although methods have 
been established to derive these levels (Barnes et al. 1987; EPA 1980a), 
uncertainties are associated with the techniques. 
 




No studies were located regarding death of humans following inhalation 
exposure to isophorone. 
 
Acute inhalation exposure of rats, guinea pigs, or mice to isophorone 
at a concentration of 619 ppm for 6 hours caused slight lacrimation during 
exposure but did not result in any deaths (Hazleton Labs 1964). Although 
this study used few animals and did not report the use of controls, the 
acute exposure level of 619 ppm probably can be considered a NOAEL for 
lethality because none of the animals of the three species tested died 
(Table 2-l and Figure 2-l). Hazleton Labs (1965a) statistically determined 
the 4-hour LC50 in rats to be 1238 ppm, with 95% confidence limits of 1008- 
1531 ppm. The LC50 is indicated in Table 2-l and Figure 2-l. Exposure to 
885 ppm for 6 hours resulted in the death of l/10 rats (Hazleton Labs 
1965a); the exposure of 885 ppm is considered the acute inhalation LOAEL for 
lethality of isophorone (see Table 2-l and Figure 2-l). The concentration 
of 885 ppm in air (Hazleton Labs 1965a) is also presented in Table l-2. The 
cause of death of the rats was not stated, but marked pulmonary congestion 
was observed. Dutertre-Catella (1976) attempted to determine the LC50 of 
isophorone in rats and rabbits, but saturation of the air at a concentration 
up to 7000 ppm for 5 hours produced mortality in only 10% of the rats and 
30% of the rabbits. The animals became comatose before death and had 
hemorrhagic lungs, vascular dilation of the alveolar capillaries and 
peribronchial vessels. Dutertre-Catella (1976) noted that at high 
concentrations of vapor, which were attained by heating isophorone, an 
appreciable quantity of the solvent remained suspended as an aerosol in the 
exposure chamber due to condensation. As the concentrations at which the 













In an intermediate duration study, l/10 female rats and 3/10 male rats 
died after being exposed to 500 ppm isophorone for 6 hours/day for up to 6 
months (Dutertre-Catella 1976). The 500 ppm concentration is presented in 
Table 2-l and plotted in Figure 2-l as the intermediate duration LOAEL for 
lethality. The concentration of 500 ppm (Dutertre-Catella 1976) is also 
presented in Table l-2. No differences in mortality were observed in rats 
compared with controls, and no deaths occurred in rabbits exposed to 250 ppm 
isophorone, 6 hours/day for 18 months (Dutertre-Catella 1976). The 250 ppm 
concentration is a chronic inhalation NOAEL for lethality in both rats and 
rabbits (see Table 2-l.and Figure 2-l). 
 
2.2.1.2 Systemic Effects 
 
Respiratory Effects, Lee and Frederick (1981) found that eye, 
respiratory, and skin irritation were among the complaints of 27/35 workers 
in a printing plant. Two of the workers (screen printers) were exposed to 
8-hour TWA concentrations of isophorone of 0.7 and 14 ppm, but it was not 
clear whether these two individuals were among those who complained of 
respiratory irritation. Lee and Frederick (1981) concluded that screen 
printers are exposed to hazardous concentrations of isophorone and other 
solvents (xylene, methylene chloride, and toluene). 
 
Very little information is available concerning the systemic effects on 
the respiratory system of animals due to inhalation exposure to isophorone. 
Isophorone is irritating to the respiratory tract of animals. DeCeaurriz et 
al. (1981a) reported that a concentration of 27.8 ppm for 5 minutes caused a 
50% decrease (RD50) in the reflex respiratory rate of mice, an indication of 
respiratory irritation. Because the lowest concentration resulting in a 
decreased respiratory rate was not indicated clearly in the study, the 27.8 
ppm level is indicated as a LOAEL for less serious respiratory effects in mice 
due to acute inhalation exposure to isophorone (see Table 2-l and Figure 2-l). 
 
Slight lung congestion was observed in rats and mice sacrificed 
immediately after exposure to 619 ppm isophorone for 6 hours, but not in 
rats or mice sacrificed 14 days after the exposure (Hazleton Labs 1964), 
suggesting reversibility of the lesion. This study used only one 
concentration (619 ppm) and did not report the use of controls. 
Nevertheless, isophorone is known to be irritating to mucous membranes (see 
Dermal/Ocular effects below), so it is reasonable to attribute the lung 
congestion to exposure to isophorone. As the congestion was not a permanent 
condition, it is not a serious adverse effect; therefore, the 619 ppm level 
is indicated in Table 2-l and Figure 2-l as a LOAEL for less serious effects 
on the respiratory system due to acute inhalation exposure to isophorone. 
Rats and rabbits that were exposed to isophorone at concentrations up to 
7000 ppm for 5 hours died and had hemorrhagic lungs with vascular dilation 
of the alveolar capillaries and peribronchial vessels (Dutertre-Catella 
1976). The concentration of 7000 ppm cannot be considered a LOAEL because 








concentrations less than 7000 ppm. Moreover, Dutertre-Catella (1976) noted 
that at 7000 ppm, a considerable quantity of the isophorone was present in 
the exposure atmosphere as an aerosol rather than as a vapor. The 
concentration of 27.8 ppm in air (DeCeaurriz et al. 1981a) was rounded to 28 
mm, and the concentration of 619 ppm in air was rounded to 620 ppm 
(Hazleton Labs 1964) for presentation in Table 1-2. 
 
Severe lung injury consisting of congestion, necrosis, and 
degeneration was reported in rats and guinea pigs exposed intermittently to 
100 ppm, but not to 25 ppm, isophorone for 6 weeks (Smyth et al. 1942). 
According to Rowe and Wolf (1963), however, later investigation led to the 
conclusion that the isophorone used by Smyth et al. (1942) contained several 
highly volatile impurities, a fact unknown to the investigators at the time. 
These impurities could have contributed to the severity of the observed 
effects. Moreover, Rowe and Wolf (1963) argued that some of the vapor 
concentrations reported by Smyth et al. (1942) were higher than could 
possibly be achieved under the conditions employed and some were 
overestimated because the vapor concentrations of the impure commercial 
product within the exposure chamber were determined using an interferometer 
that had been calibrated against pure isophorone. 
 
These criticisms of the Smyth et al. (1942) study have also been noted 
by NTP (1986) and ACGIH (1986). Given the uncertainty regarding the results 
and the exposure levels reported by Smyth et al. (1942), it is 
inappropriate to consider this study for the determination of levels of 
significant exposure. 
 
Hazleton Labs (1968) found no treatment-related histopathological 
lesions in lungs of rats exposed intermittently to 37 ppm for 4 weeks 
compared with controls. The 37 ppm concentration was the only one tested, 
and histological examination was limited to 30% of the control and treated 
rats. Although the limited histological examination could have missed lung 
lesions in the rats that were not examined (70%), no exposure-related 
histopathological lesions were observed in the lungs of rats exposed to 500 
ppm isophorone for up to 6 months or in rats and rabbits exposed to 250 ppm 
for 18 months (Dutertre-Catella 1976). The NOAELs for respiratory effects 
of 500 ppm in rats for intermediate duration exposure and 250 ppm in rats 
and rabbits for chronic exposure are presented in Table 2-1 and Figure 2-1. 
 
Hematological Effects. No studies were located regarding 
hematological effects in humans following inhalation exposure to 
isophorone. 
 
Hematological effects of inhalation exposure of animals to isophorone 
are not well documented. No studies were located regarding hematological 
effects in animals following acute inhalation exposure to isophorone. 
Hazleton Labs (1968) compared the hematological effects of inhalation 
exposure to isophorone with those of three other ketones in rats. The 








pre-exposure values. No extreme variations occurred.in any group, but the 
isophorone-exposed group (37 ppm for 4 weeks) had an increased percentage of 
lymphocytes (3% in males, 5.8% in females), decreased percentage of 
neutrophils (2.8% in males, 5.0% in females), and increased hemoglobin 
content (1.2-1.4 g/100 ml) compared with the pre-exposure values. Since 
statistical analysis was not performed, the significance of these findings 
is not known. The control males also displayed this trend. Because the 
variations in the isophorone-treated group were slight, and similar to those 
observed in the unexposed animals, the 37 ppm concentration can be 
considered a NOAEL for hematological effects of intermediate duration 
inhalation exposure to isophorone. No exposure-related hematological 
effects were observed in rats or rabbits exposed to 250 ppm isophorone for 
18 months (Dutertre-Catella 1976), which is a NOAEL for chronic exposure. 
The NOAELs are presented in Table 2-l and Figure 2-l. 
 
Hepatic Effects. No studies were located regarding hepatic effects in 
humans following inhalation exposure to isophorone. 
 
No studies were located regarding hepatic effects in animals following 
acute inhalation exposure to isophorone. In the Hazleton Labs (1968) 4-week 
study, rats exposed to 37 ppm had statistically significant decreased mean 
absolute liver weights and statistically significant decreased mean liverto- 
body weight ratios compared with controls. Histological examination of 
the livers of 30% of the rats revealed no treatment-related liver lesions; 
therefore, the toxicological significance of the decreased liver weight is 
probably minimal. As 70% of the rats in each group were not examined 
histologically, however, the possibility exists that histopathological liver 
lesions were missed. No exposure-related histopathological liver lesions 
occurred in rats exposed to 500 ppm isophorone for up to 6 months, but 
cytoplasmic microvacuolization of hepatocytes was observed in rats and 
rabbits exposed to 250 ppm isophorone for 18 months (Dutertre-Catella 1976). 
The NOAEL of 500 ppm for intermediate duration exposure and the LOAEL of 250 
ppm for chronic exposure are presented in Table 2-l and Figure 2-l. The 
concentration of 500 ppm in air (Dutertre-Catella 1976) is also presented in 
Table l-2. 
 
Renal Effects. No studies were located regarding renal effects in 
humans following inhalation exposure to isophorone. 
 
No studies were located regarding kidney effects in animals following 
acute inhalation exposure to isophorone. Smyth et al. (1942) found severe 
kidney damage, consisting of congestion, necrosis, and degeneration, in rats 
and guinea pigs exposed intermittently to 100 ppm isophorone for 6 weeks. 
As noted, however, Rowe and Wolf (1963) criticized this study for using 
impure isophorone and overestimating the exposure concentrations. Therefore 
the 100 ppm level cannot be considered the LOAEL for serious effects on the 








In the Hazleton Labs (1968) 4-week study, no treatment-related 
histopathological effects on the kidney were found in rats exposed to 37 
ppm. Because the histological examination was performed on only 30% of the 
treated and control rats, however, the possibility exists that renal lesions 
were missed. The 37 ppm concentration can be considered an intermediate 
duration NOAEL for kidney effects, however, because no exposure-related 
renal effects were detected upon urinalysis and histological examination of 
rats and rabbits that were exposed to isophorone in air at a concentration 
of 250 ppm for 18 months (Dutertre-Catella 1976). The NOAELs of 37 ppm for 
intermediate duration and 250 ppm for chronic exposure are presented in 
Table 2-l and Figure 2-l. 
 
Dermal/Ocular Effects. Isophorone is irritating to the eyes and 
mucous membranes of humans. Several studies have attempted to determine the 
thresholds for eye, nose, and throat irritation for isophorone in humans. 
As seen from Table 2-1, when the exposure duration was 15 minutes, 10 ppm 
was tolerated, while 25 ppm produced irritation to the eye, nose, and throat 
(Silverman et al. 1946). NIOSH (1978a) noted that Silverman et al. (1946) 
did not discuss acclimatization. In another study, when the exposure 
duration was 7 minutes, no irritation was reported at 18 ppm, but the 
threshold for throat irritation was 35 ppm. Eye and nose irritation 
occurred at 65 ppm, but not at 35 ppm (Hazleton Labs 1965b). Since no 
exposure concentrations between 35 and 65 ppm were tested, the threshold for 
eye and nose irritation falls between these concentrations. The subjects 
were retested after 2 weeks, with no significant difference between the 
trials. Thus, these thresholds appear to be reliable, although there was 
some concern that the concentrations were slightly overestimated because the 
isophorone may not have vaporized completely. Furthermore, only six 
subjects per group were tested, and there was substantial individual 
variability in response. Smyth and Seaton (1940) reported that exposure of 
humans for a few minutes to 40-400 ppm resulted in eye, nose, and throat 
irritation at all exposures, but Rowe and Wolf (1963) criticized this study 
for using impure isophorone and overestimating the exposure concentrations. 
The NOAELs and LOAELs for irritation due to 7 and 15 minutes of exposure in 
the studies by Silverman et al. (1946) and Hazleton Labs (1965b) are 
indicated in Table 2-l and Figure 2-l. The concentration of 25 ppm in air 
(Silverman et al. 1946) is presented in Table l-l. 
 
The irritancy properties of isophorone have also been observed in 
humans exposed occupationally to isophorone. In an industrial hygiene 
survey, Kominsky (1981) reported that the eye and nose irritation 
complained of by a screen printer could'have been caused by 4-minute 
exposure to 25.7 ppm isophorone, which was measured in the personal 
breathing zone while the worker was washing a screen. Lee and Frederick 
(1981) found that eye, respiratory, and skin irritation were among the 
complaints of 27/35 workers in a printing plant where isophorone and other 
solvents (xylene, methylene chloride, and toluene) were used. On the day of 
measurement, two of the screen printers were found to be exposed to 8-hour 








whether these two individuals were among the workers complaining of 
irritation. The odor threshold for isophorone in air has been reported to 
be 0.2 ppm (v/v) (Amoore and Hautala 1983). 
 
Isophorone is also irritating to animals. Smyth et al. (1942) 
reported conjunctivitis and skin irritation in rats and guinea pigs exposed 
to isophorone at high concentrations; as discussed above, however, Rowe and 
Wolf (1963) criticized this study for using impure isophorone and for 
overestimating the exposure concentrations. As discussed above for 
respiratory effects, a concentration of 27.8 ppm for 5 minutes caused a 50% 
decrease (RD50) in the reflex respiratory rate of mice, which indicated 
sensory irritation rather than a neurological effect (DeCeaurriz et al. 
1981a). Irritation of the eyes and nasal mucosa was observed in rats 
exposed to 500 ppm isophorone in air for up to 6 months and rats and rabbits 
exposed to 250 ppm for 18 months (Dutertre-Catella 1976). These LOAELs for 
intermediate and chronic duration exposure are presented in Table 2-l and 
Figure 2-l. The 250 ppm concentration is also presented in Table 1-2. 
 
Other Systemic Effects. In the 4-week Hazleton Labs (1968) study, 
exposure of rats to 37 ppm resulted in statistically significant decreased 
body weight gain. The 37 ppm level can be considered a LOAEL for less 
serious effects for intermediate inhalation exposure to isophorone (see 
Table 2-l and Figure 2-l). The concentration of 37 ppm in air is presented 
in Table l-2. 
 
2.2.1.3 Immunological Effects 
 
No studies were located regarding immunological effects in humans or 
animals following inhalation exposure to isophorone. 
 
2.2.1.4 Neurological Effects 
 
Isophorone affects the central nervous system. In an industrial 
hygiene survey report, Lee and Frederick (1981) attributed dizziness 
complained of by workers to exposure to isophorone and other solvents 
(xylene, toluene, methylene chloride). In a communication to the American 
Conference of Governmental Industrial Hygienists, Ware (1973) reported that 
employees exposed for 1 month to 5-8 ppm isophorone complained of fatigue 
and malaise. Complaints stopped when workroom exposure levels of isophorone 
were lowered to l-4 ppm. This communication formed the basis for 
establishing the ACGIH Ceiling Limit of 5 ppm for isophorone (ACGIH 1986). 
Thus, 5 ppm can be considered a LOAEL and the range of l-4 ppm a NOAEL for 
neurological effects in humans due to intermediate inhalation exposure to 
isophorone (see Table 2-l and Figure 2-l). The concentration of 5 ppm in 
air (Ware 1973) is presented in Table l-l. 
 
Neurological effects of inhalation exposure to isophorone also have 
been reported in animals. Narcosis and ataxia occurred in rats and guinea 








but Rowe and Wolf (1963) noted that this study used impure isophorone and 
overestimated the concentrations. DeCeaurriz et al. (1984) found doserelated 
neurobehavioral effects (decreased immobility in a behavioral 
despair swimming test) in.mice exposed for 4 hours. The lowest 
concentration resulting in the behavioral effects was 89 ppm, which is 
indicated as a less serious LOAEL in Table 2-1 and Figure 2-1. The 
concentration of 89 ppm in air (DeCeaurriz et al. 1984) is presented in 
Table l-2. 
 
DeCeaurriz et al. (1981b) also reported that inhalation of isophorone 
for 4 hours by mice increased the threshold for onset of seizures produced 
by intravenous administration of pentrazole, indicating that isophorone 
depressed the central nervous system. The concentration of isophorone that 
resulted in a 50% increase in the seizure threshold (STI50) was 131 ppm 
(LOAEL for less serious effects on Table 2-1 and Figure 2-l), with 95% 
confidence intervals of 113-145 ppm. At the 4-hour LC50 of 1238 ppm and 
higher, rats were ataxic and comatose during exposure, after which they 
displayed depression and inactivity (Hazleton Labs 1965a). The 1238 ppm 
concentration is indicated as a LOAEL for serious effects in Table 2-1 and 
Figure 2-1. These effects were not noted at 885 ppm. Althohgh the 
exposure concentration of 885 ppm did not result in overt signs of 
neurotoxicity, more sensitive tests for neurotoxicity (e.g., operant 
performance, motor activity, electrophysiology), which may have revealed 
neurobehavioral effects at this level, were not performed, Therefore, the 
concentration of 885 ppm should not be considered a NOAEL for neurotoxicity 
for acute inhalation exposure. Rats and rabbits that were exposed to 
isophorone for 5 hours at concentrations up to 7000 ppm became comatose and 
died (Dutertre-Catella 1976). The concentration of 7000 ppm cannot be 
considered a LOAEL because it was not clear from the report whether the 
animals became comatose at concentrations less than 7000 ppm. Furthermore, 
at high concentrations, a considerable amount of isophorone was present in 
the exposure atmosphere as an aerosol rather than as a vapor (Dutertre- 
Catella 1976). 
 
2.2.1.5 Developmental Effects 
 
No studies were located regarding developmental effects in humans 
following inhalation exposure to isophorone. 
 
As part of an intermediate duration study, in which rats were exposed 
to 500 ppm isophorone in air, Dutertre-Catella (1976) mated exposed males 
with exposed females, control males with exposed females, exposed males with 
control females, and control males with control females after 3 months of 
exposure. Exposure of females continued throughout gestation, and they were 
allowed to deliver. No differences in pregnancy rate or litter size and no 
abnormalities in pups were found. The pups were not examined for internal 
malformations; therefore, this study was inadequate to determine 








In a pilot developmental toxicity study, pregnant rats and mice were 
exposed by inhalation to isophorone at concentrations up to 150 ppm on days 
6-15 of gestation (Bio/dynamics 1984a). Dose-related mild maternal toxicity 
(increased liver weight and clinical signs) occurred at all concentrations 
(≥50 ppm) in rats, but there was no clear indication of maternal toxicity in 
mice. Exencephaly was observed in one late resorption in one litter in the 
high-concentration group of rats, and in one late resorption in one litter 
and in two live fetuses in another litter in the high-concentration group of 
mice. Because this was a pilot study, only 12 female rats and 12 female 
mice were used, and the fetuses were examined only for gross abnormalities. 
A second, more complete developmental toxicity study was also performed in 
two species. Groups of 22 female rats and 22 female mice were exposed on 
gestation days 6-15 to concentrations of isophorone up to 115 ppm 
(Bio/dynamics 1984b). In rats, dose-related maternal toxicity (alopecia) 
was seen at all concentrations (≥25 ppm). In addition, rat dams exposed to 
115 ppm had lower body weights than controls on some days. No other 
indications of maternal toxicity were noted. There was a statistically 
significant reduction in mean crown-rump length among rat fetuses, but not 
among litters, in the group exposed to 115 ppm. In mice, the only effect 
noted was that the mean body weight of dams exposed to 115 ppm isophorone 
was decreased during one day of the treatment period. Bio/dynamics (1984b) 
concluded that isophorone was not teratogenic or fetotoxic in rats or mice 
at concentrations up to 115 ppm. This conclusion is not supported by the 
results. Although significance across litters was not reached, the 
reduction in crown-rump length in the offspring of rats exposed to 115 ppm 
is evidence of growth retardation. Several deviations from the protocol 
resulted in the failure to perform some of the scheduled fetal examinations. 
Bio/dynamics (1984b) stated that these deviations did not alter the 
conclusions. Based on the findings of the second study, Bio/dynamics 
(1984b) did not regard the occurrences of exencephaly in the pilot study to 
be treatment-related. This conclusion is untenable because the second study 
did not test isophorone at 150 ppm, the exposure level at which the 
exencephaly was observed. Thus, the findings in the pilot study are 
difficult to interpret; the incidences of exencephaly/litter at the 150 ppm 
exposure were not significantly different from controls, but this 
malformation was observed only at the 150 ppm exposure level. Furthermore, 
the malformation was seen in both species. Although these results are 
inconclusive, 150 ppm may be a serious LOAEL for malformations in rats and 
mice, and 115 ppm may be a NOAEL in mice. The concentration of 115 ppm in 
rats, however, was associated with growth retardation and represents a 
serious LOAEL for developmental effects of inhalation exposure. The NOAEL 
for rats is 100 ppm, which was the next lower dose in the Bio/dynamics 
(1984a,b) studies. The NOAELs and LOAELs are indicated in Table 2-l and 
Figure 2-l. 
 
2.2.1.6 Reproductive Effects 
 
As discussed above in Section 2.2.1.5, no differences in pregnancy rate 








for 3 months before mating (Dutertre-Catella 1976). Since this study did 
not examine other parameters of reproductive toxicity, 500 ppm cannot be 
considered a NOAEL for reproductive effects. 
 
2.2.1.7 Genotoxic Effects 
 
No studies were located regarding genotoxic effects in humans or 




No studies were located regarding cancer in humans or animals following 
inhalation exposure to isophorone. 
 
2.2.2 Oral Exposure 
 
No studies were located regarding health effects in humans following 




The oral LD50 of isophorone was reported as 3450 mg/kg in male rats 
(Hazleton Labs 1964) and 2104-2150 mg/kg in female rats (Smyth et al. 1969, 
1970). LD50 values of 2700 ± 200 mg/kg for male rats, 2100 ± 200 mg/kg for 
female rats, and 2200 ± 200 mg/kg for male mice also were reported by 
Dutertre-Catella (1976). The value reported by Hazleton Labs (1964) was 
estimated because the mortality data did not lend itself to statistical 
analysis. Furthermore, the doses were widely spaced, and the animals were 
fasted for only 3-4 hours before dosing, which could have interfered with 
gastrointestinal absorption of isophorone. Necropsy of rats that died 
revealed congestion of the lungs, kidneys, adrenals, and pancreas, and 
gastrointestinal inflammation. Necropsy of rats that survived the 14-day 
observation period revealed no effects. The studies by Smyth et al. (1969, 
1970) were determinations of the joint toxic action of 27 pairs of 
industrial solvents (see Section 2.7 on Interactions with other chemicals), 
but the details of the individual LD50 determinations and the cause of death 
were not provided. Nevertheless, the values for isophorone were 
reproducible in the two studies by Smyth et al. (1969, 1970). The reason 
for the sex difference is not apparent. The LD5Os are indicated in Table 
2-2 and Figure 2-2. No short-term studies of isophorone administered in 
food or drinking water were located. The LD50 of -2100 mg/kg, which was 
determined using liquid isophorone by gavage (Smyth et al. 1969, 1970), was 
converted to an equivalent concentration of 15,000 ppm in water for 
presentation in Table l-4. 
 
Lethality data for intermediate duration oral exposure to isophorone 
are provided for 16 days and for 13 weeks of exposure in the NTP (1986) 
study. For the 16-day experiment, Table 2-2 and Figure 2-2 indicate 2000 













lethality in rats and mice. For the 13-week study, ,100O mg/kg/day is the 
LOAEL for lethality and 500 mg/kg/day is the NOAEL for lethality in mice 
(see Table 2-2 and Figure 2-2). Although the deaths were considered to be 
related to isophorone exposure, NTP (1986) did not comment on the cause of 
death. At 1000 mg/kg/day in the 13-week study, one female rat died during 
week 5, but NTP (1986) did not comment on whether this death was considered 
to be related to isophorone exposure. 
 
In the chronic exposure experiment by NTP (1986), male rats treated 
with 500 mg/kg/day (LOAEL for lethality due to chronic oral exposure on 
Table 2-2 and Figure 2-2) showed increased mortality, while no increased 
mortality was observed at 250 mg/kg/day (NOAEL on Table 2-2 and Figure 2-2). 
NTP (1986) regarded the increased mortality in the male rats to be related 
to treatment with isophorone, but the cause was not attributed to lesions in 
any one particular organ system. The increased mortality occurred late in 
the study (after 96 weeks). No long-term studies of isophorone administered 
in food or drinking water demonstrating increased mortality were located. 
The dose levels of 1000 and 2000 mg/kg/day, which were administered to mice 
by gavage in corn oil for 16 days and 13 weeks (NTP 1986), respectively, 
were converted to equivalent concentrations of 8000 and 15,000 ppm in food 
for presentation in Table l-4. 
 
2.2.2.2 Systemic Effects 
 
No reliable studies were located regarding the systemic effects in 
animals following acute oral exposure to isophorone. 
 
Gastrointestinal Effects. In generally well-conducted, comprehensive 
go-day studies, no treatment-related grossly or histologically observable 
lesions were found in the gastrointestinal tract of rats and mice dosed by 
gavage with isophorone (NTP 1986), rats exposed to isophorone in the diet 
(AME Inc 1972a), or dogs treated with isophorone in gelatine capsules (AME 
Inc 1972b). The studies by AME Inc (1972a,b) had several limitations, which 
include lack of reporting of chemical analysis of feed formulations and 
statistical methods in the rat study, and failure to examine all animals 
histologically in both studies. Despite the limitations, the results 
reported for gastrointestinal effects, as well as for other endpoints, are 
probably valid because the doses are lower than the NOAELs for the same 
endpoints in the NTP (1986) go-day (13-week) study. The highest doses 
administered in these studies were 311.8 mg/kg/day in the diet in rats (AME 
Inc 1972a), 1000 mg/kg/day by gavage in rats and mice (NTP 1986), and 150 
mg/kg/day in dogs (AME Inc 1972b), which are indicated as NOAELs for 
systemic toxicity due to intermediate oral exposure in Table 2-2 and Figure 
2-2. 
 
In the chronic gavage study by NTP (1986), hyperkeratosis of the 
forestomach was observed in isophorone-treated mice at both doses (Table 2-2 
and Figure 2-2), but not in rats. The lowest dose of 250 mg/kg/day is 
indicated as a LOAEL for less serious gastrointestinal effects due to 
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chronic oral exposure to isophorone. No long-term studies of isophorone
administered in food or drinking water demonstrating gastrointestinal
effects were located. The dose level of 250 mg/kg/day, which was
administered by gavage in corn oil (NTP 1986), was converted to an
equivalent concentration of 1900 ppm in food for presentation in Table l-4.
Hepatic Effects. No significant differences between pre-exposure and
post-exposure levels of serum electrolytes, blood glucose and sulfhydride
radicals, SGOT, SGPT, serum creatine phosphokinase, or serum lactic
dehydrogenase were found in rabbits treated by gavage with isophorone at a
dose of 1000 mg/kg/day, 2 days/week for 2 weeks (Dutertre-Catella 1976). No
other indices of liver toxicity were examined; therefore, the dose of 1000
mg/kg/day cannot be considered a NOAEL for liver effects. In the go-day
studies conducted by NTP (1986) and AME Inc (1972a,b), no treatment-related
grossly or histologically observable lesions were found in the livers of
rats and mice dosed by gavage with isophorone (NTP 1986), rats treated with
isophorone in the diet (AME Inc 1972a), or dogs treated with isophorone in
gelatine capsules (AME Inc 1972b). These studies were comprehensive and
generally well-conducted. The highest doses administered in these studies
were 311.8 mg/kg/day in the diet in rats (AME Inc 1972a), 1000 mg/kg/day by
gavage in rats and mice (NTP 1986), and 150 mg/kg/day in dogs (AME Inc
1972b), which are indicated as NOAELs for systemic effects due to
intermediate oral exposure in Table 2-2 and Figure 2-2.
No treatment-related gross or histopathological lesions in the liver
were observed in rats in the chronic experiment by NTP (1986), but dosed
male mice had increased coagulative necrosis and hepatocytomegaly, along
with increased incidences of hepatocellular adenomas and carcinomas (see
Section 2.2.2.8 on carcinogenicity). Female mice, however, did not have
treatment-related lesions in the liver. The highest dose (500 mg/kg/day) is
indicated as a NOAEL for liver effects in rats, while the low dose (250
mg/kg/day) is indicated as a LOAEL for non-neoplastic liver lesions in mice
due to chronic oral exposure to isophorone (see Table 2-2 and Figure 2-2).
No long-term studies of isophorone administered in food or drinking water
demonstrating hepatic effects were located. The dose level of 250
mg/kg/day, which was administered.by gavage in corn oil (NTP 1986), was
converted to an equivalent concentration of 1900 ppm in food for
presentation in Table l-4.
Renal Effects. Gross and histological examination of the kidneys of
rats and mice treated with isophorone by gavage (NTP 1986), rats fed diets
containing isophorone (AME Inc 1972a), or dogs treated with isophorone in
gelatine capsules (AME Inc 1972b) for 90 days revealed no treatmentrelated
lesions. In the NTP (1986) go-day studies, recuts and special
stains of kidney tissues were performed to confirm the lack of response on
the kidney. Thus, the highest doses administered in these studies (311.8
mg/kg/day in the diet in rats, 1000 mg/kg/day by gavage in rats and mice,
and 150 mg/kg/day in dogs (AME Inc 1972b) are NOAELs for systemic effects








The kidney is a target organ for chronic oral exposure to isophorone. 
In the NTP (1986) study, dosed male mice, but not female mice, had increased 
incidences of chronic focal inflammation of the kidney, but no other 
lesions. The 500 mg/kg/day dose is indicated as a LOAEL for less serious 
renal effects in mice due to chronic oral exposure in Table 2-2 and Figure 
2-2. Dosed male rats had increased incidences of tubular cell hyperplasia 
(possibly pre-neoplastic), epithelial cell hyperplasia of the renal pelvis, 
and tubular mineralization at both doses. The incidence of tubular 
mineralization was higher in low dose males than in high dose males, and was 
coincident with chronic nephropathy, the incidence of which was also higher 
at the low dose. For this reason, NTP (1986) stated that the nephropathy 
was probably not the cause of the increased mortality in the high dose 
males. Male rats also had increased incidences of tubular cell adenomas and 
carcinomas (see Section 2.2.2.8 on carcinogenicity). As discussed in 
Section 2.3 (Relevance to Public Health), the tubular cell lesions may be 
unique to male rats. Dosed female rats had increased incidences of 
nephropathy, which may have been related to isophorone exposure. The dose 
of 250 mg/kg/day is indicated as a LOAEL for less serious effects on the 
kidney in rats for chronic oral exposure to isophorone in Table 2-2 and 
Figure 2-2. No long-term studies of isophorone administered in food or 
drinking water demonstrating renal effects were located. The dose level of 
250 mg/kg/day, which was administered by gavage in corn oil (NTP 1986), was 
converted to an equivalent concentration of 5000 ppm in food for 
presentation in Table 1-4. 
 
Other Systemic Effects. Mean body weight gain was decreased in rats 
treated by gavage with isophorone at 1000 mg/kg/day, but not at 500 
mg/kg/day in a 16-day experiment by NTP (1986). The mice in the 16-day 
study did not have decreased growth. Body weight changes were not 
consistent or dose-related in the rats or mice treated with up to 1000 
mg/kg/day in the 13-week experiment or up to 500 mg/kg/day in the 103-week 
experiment (NTP 1986). Male rats treated with 233.8 mg/kg/day had transient 
decreases in body weight gain during the go-day feeding study by AME Inc 
(1972a), but body weights were not significantly different from controls at 
the end of the study. As 1000 mg/kg/day was a NOAEL for body weight changes 
in rats and mice in 13-week experiments, the decreased mean body weight at 
the same dose in the 16-day study cannot be considered an adverse effect. 
Therefore, 1000 mg/kg/day is a NOAEL for body weight changes in rats and 
mice for intermediate duration exposure. 
 
In the well-conducted, comprehensive go-day studies, no treatmentrelated 
grossly or histologically observable lesions were found in the lungs, hearts, 
hematopoietic tissues, or in the skin or eyes of rats and 
mice dosed by gavage with isophorone (NTP 1986), rats treated with 
isophorone in the diet (AME Inc 1972a), or dogs treated with isophorone in 
gelatine capsules (AME Inc 1972b). Furthermore, no changes in 
hematological indices and no histopathological lesions in the skeletal 
muscle were found in rats or dogs in the studies by AME Inc (1972a,b). The 
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highest doses administered in these studies were 311.8 mg/kg/day in the diet
in rats (AME Inc 1972a), 1000 mg/kg/day by gavage in rats and mice (NTP
1986), and 150 mg/kg/day in dogs (AME Inc 1972b), which are indicated as
NOAELs for systemic effects due to intermediate oral exposure in Table 2-2
and Figure 2-2.
A minimal risk level (MRL) for intermediate oral exposure can be
derived from the NOAELs for systemic endpoints. The highest NOAELs for
systemic effects of intermediate oral exposure were the 1000 mg/kg/day
doses in rats and mice in the 13-week (NTP 1986) study. Increased
mortality was observed in mice at 1000 mg/kg/day, however, precluding the
use of this dose. Based on the dose of 311.8 mg/kg/day in rats (AME Inc
1972a), an intermediate duration oral MRL of 3 mg/kg/day was calculated, as
described in the footnote in Table 2-2. The MRL for intermediate exposure
can be compared to existing State and Federal criteria levels (see Chapter
7) or to amounts of the chemical encountered in environmental or
occupational situations (see Chapter 5).
Other than the gastrointestinal, hepatic, and renal lesions described
above, no treatment-related gross or histopathological lesions were observed
in the lungs, heart, hematopoietic organs, skin, or other organs and tissues
of rats and mice in the chronic experiment by NTP (1986). There was a dose-
related increased incidence of fatty metamorphosis of the adrenal cortex in
the male rats, but NTP (1986) stated that the biological significance of
this observation is not known. The highest dose (500 mg/kg/day) is
indicated as a NOAEL for systemic effects other than gastrointestinal,
hepatic, and renal toxicity due to chronic oral exposure to isophorone
(Table 2-2 and Figure 2-2). As discussed above under these endpoints, the
LOAEL for gastrointestinal, hepatic, and renal effects is 250 mg/kg/day, (as
the dose was given 5 days/week, it is equivalent to 179 mg/kg/day). A MRL
for chronic oral exposure can be derived from the LOAELs for systemic
effects. Based on the dose of 179 mg/kg/day, a chronic oral MRL of 0.2
mg/kg/day was calculated as described in the footnote to Table 2-2. The MRL
has been converted to an equivalent concentration in food (7 ppm) for
presentation in Table 1-3.
2.2.2.3 Immunological Effects
No studies were located regarding immunological effects in animals
following acute oral exposure to isophorone.
Histological examination of organs and tissues of the immune system did
not reveal any effects in rats or mice treated by gavage with isophorone.for
13 or 103 weeks (NTP 1986), in rats treated with isophorone in the diet for
13 weeks (AME Inc 1972a), or in dogs treated with isophorone in gelatine
capsules for 13 weeks (AME Inc 1972b). In none of these studies, however,
were specific tests of immune function performed. Such tests of immune








histological examinations. Therefore, the doses used in these studies 
cannot be considered NOAELs for effects on the immune system. 
 
2.2.2.4 Neurological Effects 
 
Neurological effects of isophorone have been observed in animals after 
oral dosing. In an acute study, rats treated by gavage with isophorone at 
5000 mg/kg displayed depression, ptosis, absence of righting reflex, and 
prostration (LOAEL for serious effects due to acute oral exposure on Table 
2-2 and Figure 2-2); 4/5 died within 2 days after dosing (Hazleton Labs 
1964). At 1450 mg/kg, depression was observed but the rats recovered within 
2 days (LOAEL for less serious effects for acute oral exposure in Table 2-2 
and Figure 2-2). No signs of neurotoxicity occurred at 417 mg/kg. In the 
16-day NTP (1986) study, mice treated by gavage at 1000 mg/kg/day, but not 
at 500 mg/kg/day, staggered after dosing, indicating an acute response to 
the high dose. Similarly, in the 13-week NTP (1986) study, rats given 1000 
mg/kg/day, but not 500 mg/kg/day, were sluggish and lethargic after dosing, 
also indicating an acute response to the high dose. Therefore, 1000 mg/kg 
is the acute LOAEL for less serious neurological effects (Table 2-2 and 
Figure 2-2). Although the doses of 417 mg/kg and 500 mg/kg did not result 
in overt signs of neurotoxicity, more sensitive tests for neurotoxicity 
(e.g., operant performance, motor activity, electrophysiology), which may 
have revealed neurobehavioral effects at these doses, were not performed. 
Therefore, these doses should not be considered NOAELs for neurotoxicity for 
oral exposure. No short-term studies of isophorone administered in food or 
drinking water were located. The dose level of 1000 mg/kg in mice, which 
was administered by gavage in corn oil (NTP 1986), was converted to an 
equivalent concentration of 8000 ppm in food for presentation in Table l-4. 
 
2.2.2.5 Developmental Effects 
 
No studies were located regarding developmental effects in humans or 
animals following oral exposure to isophorone. 
 
2.2.2.6 Reproductive Effects 
 
No studies were located regarding reproductive effects in animals 
following acute oral exposure to isophorone. 
 
Histological,examination of reproductive organs did not reveal any 
effects in rats or mice treated by gavage with isophorone for 13 or 103 
weeks (NTP 1986), in rats treated with isophorone in the diet for 13 weeks 
(AME Inc 1972a), or in dogs treated with isophorone in gelatine capsules for 
13 weeks (AME Inc 1972b). In none of these studies, however, were specific 
tests of reproductive function performed, which would be necessary to rule 
out an effect. Therefore, the doses used in these studies cannot be 




No studies were located regarding genotoxic effects in humans or
animals following oral exposure to isophorone.
2.2.2.8 Cancer
In the chronic gavage study, NTP (1986) concluded that there is "some
evidence of carcinogenicity" in male rats due to an increased incidence of
relatively rare renal tubular cell adenomas and adenocarcinomas at 250 and
500 mg/kg/day and rare preputial gland carcinomas at 500 mg/kg/day.
According to the strict criteria of NTP, "some evidence" in this case means
that the study showed a slight increase in uncommon malignant or benign
neoplasms. The 250 and 500 mg/kg/day doses are indicated in Table 2-2 and
Figure 2-2 as effect levels for carcinogenicity (Cancer Effect Levels, CELs)
in rats due to oral exposure to isophorone. Based on the combined
incidences of renal tubular cell tumors and preputial gland tumors, EPA
(1986, 1987b) proposed an oral q1* of 4.1 x 10
-3 (mg/kg/day)-1 for
isophorone, but this analysis is under review by the EPA.
In the NTP (1986) study, male mice had marginally increased
incidences of hepatocellular tumors and mesenchymal tumors of the
integumentary system at 500 mg/kg/day and of malignant lymphomas at 250
mg/kg/day. NTP (1986) considered this evidence to be equivocal because the
study showed marginal increases in neoplasms related to isophorone
exposure. The doses of 250 and 500 mg/kg/day are indicated in Table 2-2 and
Figure 2-2 as CELs for carcinogenicity in mice. There was no evidence of
carcinogenicity in female rats or mice.
2.2.3 Dermal/Ocular Exposure
No studies were located regarding health effects in humans following
dermal or ocular exposure to isophorone.
2.2.3.1 Death
Hazleton Labs (1964) reported that the dermal LD50 of isophorone in
rabbits was greater than 3160 mg/kg, the highest dose tested. In this study,
the area of application was occluded for 24 hours. Union Carbide (1968),
however, reported 1.5 mL/kg (1384 mg/kg) as the dermal LD50 in rabbits, but
no details of the determination were provided. Therefore, it is not
possible to reconcile these contradictory reports, Dutertre-Catella (1976)
estimated a dermal LD50 of 1200 mg/kg in rabbits. The LD50 was difficult to
determine with precision because some rabbits died within 6 hours of
application and the method requires that the chemical remain on the skin for
24 hours. The rabbits that did not die within 6 hours recovered and were
not harmed by doses up to 4000 mg/kg. The dermal LD50 is indicated on










rats for 8 weeks, 20% of the males but none of the females died (Dutertre- 
Catella 1976) (Table 2-3). No studies were located regarding death of 
animals following chronic duration exposure to isophorone. 
 
2.2.3.2 Systemic Effects 
 
Dermal/Ocular Effects. Skin irritation was observed in rabbits and 
guinea pigs following dermal application of isophorone (Eastman Kodak 1967; 
Hazleton Labs 1964; Potokar et al. 1985; Truhaut et al. 1972). In these 
studies, undiluted isophorone generally in a volume of 0.5 ml (Table 2-3) 
was applied to the clipped skin of the animals and held under an occlusive 
covering. Hazleton Labs (1964) reported doses in units of mg/kg and found 
that ≥200 mg/kg (LOAEL for less serious effects) resulted in desquamation 
and erythema, while 50 mg/kg (NOAEL) was without effect. Application of 0.1 
or 0.2 mL isophorone to the shaved skin of rats for 8 weeks resulted in 
erythema and scar tissue formation (Dutertre-Catella 1976). These effects 
disappeared rapidly after exposure ceased. These doses are indicated in 
Table 2-3. 
 
Isophorone is also irritating to the eyes of rabbits. Application of 
0.02-0.1 ml of undiluted isophorone directly to the eye caused severe 
injury, cornea1 opacity, and necrosis (Carpenter and Smyth 1946; Hazleton 
Labs 1964; Truhaut et al. 1972) (see Table 2-3). Hazleton Labs (1964) found 
that the cornea1 damage was no longer present 14 days after exposure. No 
studies were located regarding dermal/ocular effects in animals following 
intermediate or chronic duration exposure to isophorone. 
 
Other Systemic Effects. In rabbits exposed dermally to isophorone at 
doses up to 3160 mg/kg, no systemic pathological effects were found by gross 
necropsy (Hazleton Labs 1964), but histological examinations were not 
performed. In this study, the site of application was occluded for 24 hours 
to prevent evaporation of isophorone from the skin. No significant 
differences between pre-exposure and post-exposure levels of serum 
electrolytes, blood glucose and sulfbydride radicals, SGOT, SGPT, serum 
creatine phosphokinase, or serum lactic dehydrogenase were found in rabbits 
treated dermally with 20 mL isophorone (Dutertre-Catella 1976). No other 
indices of liver toxicity were examined; therefore, the 20 mL dose cannot be 
considered a NOAEL for liver effects. 
 
2.2.3.3 Immunological Effects 
 
No studies were located regarding immunological effects in humans or 
animals following dermal or ocular exposure to isophorone. 
 
2.2.3.4 Neurological Effects 
 
In the study by Hazleton Labs (1964), l/4 rabbits exposed dermally to 
3160 mg/kg under an occlusive bandage for 24 hours displayed marked 








Table 2-3). The other three rabbits at this dosage and at ≤794 mg/kg did 
not display any signs of toxicity. 
 
No studies were located regarding the following effects in humans or 
animals following dermal or ocular exposure to isophorone: 
 
2.2.3.5 Developmental Effects 
 
2.2.3.6 Reproductive Effects 
 




2.3 RELEVANCE TO PUBLIC HEALTH 
 
Death. No information was located regarding death of humans following 
inhalation, oral, or dermal exposure to isophorone. Concentrations and 
doses causing death in animals have been reported for acute and intermediate 
duration inhalation exposures, for acute, intermediate duration, and 
chronic oral exposures, and for acute and intermediate duration dermal 
exposure. The acute lethality of isophorone in animals may be due to its 
effects on the central nervous system. Hazleton Labs (1964) found that rats 
exposed by inhalation to the LC50 were comatose, and rats treated orally 
with lethal doses displayed depression, absence of righting reflex, and 
prostration. In the gavage NTP (1986) studies, rats and mice displayed 
lethargy and staggering after dosing with 1000 mg/kg. The highest dose in 
the 16-day study (2000 mg/kg/day) was fatal to all the mice and 5/10 of the 
rats. NTP (1986) did not comment on the cause of death. In the chronic 
study, high-dose (500 mg/kg/day) male rats had increased mortality (NTP 
1986). The increased mortality, which occurred late in the study (after 96 
weeks), was considered to be related to isophorone exposure, but NTP (1986) 
could not relate the cause with effects in any specific organ system. The 
concentrations or doses of isophorone that would be required to result in 
the death of humans are not known. As mild neurological effects have been 
observed in humans exposed to relatively low levels of isophorone, it is 
likely that if humans were to be exposed to levels high enough to result in 
death, the cause may be related to more severe CNS effects. 
 
Systemic Effects. The only known effects of isophorone exposure in 
humans are eye, nose, and throat irritation, and fatigue and malaise. 
Studies were conducted in humans to determine the thresholds for eye, nose, 
and throat irritation (25-35 ppm) (Hazleton Labs 1965b; Silverman et al. 
1946). The thresholds agree reasonably well with exposure concentrations 
(≅25 ppm) associated with eye, nose, and skin irritation in occupational 
settings (Kominsky 1981; Lee and Frederick 1981). The thresholds for 
irritation are near the OSHA (1989) Permissible Exposure Limit of 25 ppm, 
and higher than the ACGIH (1988) Ceiling Limit of 5 ppm, which is based on 








Systemic effects of isophorone observed in animals include pulmonary 
congestion and hemorrhage, hyperkeratosis of the forestomach, irritation to 
the skin, eye, and mucous membranes, hematological effects, liver damage, 
and kidney damage. 
 
The hemorrhaging observed in rats and rabbits (Dutertre-Catella 1976) 
and the pulmonary congestion observed in rats and mice following acute 
inhalation exposure to isophorone (Hazleton Labs 1964) is probably related 
to irritation of mucous membranes. DeCeaurriz et al. (1981a) assessed the 
sensory irritation of isophorone in mice by measuring the decrease in the 
respiratory rates, also indicating that isophorone is irritating to the 
respiratory system. Ocular and nasal irritation also occurred in rats 
exposed to isophorone in air at 500 ppm for up to 6 months and in rats and 
rabbits exposed to 250 ppm for 18 months (Dutertre-Catella 1976). Since 
isophorone is known to be irritating to mucous membranes of humans, 
inhalation exposure probably could result in pulmonary congestion in 
h u m a n s . The highest inhalation exposures occur in occupational settings, 
however, where respiratory irritation has been reported in humans exposed to 
isophorone and other solvents. 
 
Chronic exposure of mice by gavage to isophorone at 250 mg/kg/day 
resulted in hyperkeratosis of the forestomach (NTP 1986), an effect that may 
also be related to the irritating effect on mucous membranes. Although 
there is no tissue in man that is precisely analogous to the mouse 
forestomach and the effects of oral exposure of humans to isophorone are not 
known, ingestion of isophorone could result in gastrointestinal irritation. 
The minimum concentration of isophorone in water or food necessary to 
produce the irritation cannot be determined from the available data in 
animals. 
 
Dermal exposure of rats, rabbits, and guinea pigs results in skin 
irritation (Dutertre-Catella 1976; Eastman Kodak 1967; Hazleton Labs 1964; 
Potokar et al. 1985; Truhaut et al 1972). In these studies, liquid 
isophorone was applied to the skin and the area of application was occluded 
for 24 hours to prevent evaporation, or to the shaved skin for 8 weeks. 
While it is unlikely that a human would be exposed in such a manner, screen 
printers are exposed dermally to both the vapor and the liquid forms of 
isophorone, which could result in irritation of unprotected skin. 
 
Application of undiluted isophorone to the eyes of rabbits results in 
severe eye injury (Carpenter and Smyth 1946; Hazleton Labs 1964; Truhaut et 
al. 1972), which appears to be reversible with time (Hazleton Labs 1964). 
Isophorone is known to be irritating to the eyes of humans exposed to the 
vapors (Hazleton Labs 1968; Silverman et al. 1946); it is reasonable to 
conclude that liquid isophorone splashed directly into the eyes of humans 
could cause severe eye injury. 
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When post-exposure values were compared with pre-exposure values,
slight changes in the percentage of white blood cells and slightly increased
hemoglobin content were observed in rats exposed to isophorone by inhalation
(Hazleton Labs 1964), but similar changes also occurred in controls.
Therefore, toxicological significance of this finding is minimal and the
relevance to humans is not known.
Reported effects on the liver include decreased liver weight in rats
exposed subchronically by inhalation (Hazleton Labs 1968), cytoplasmic
microvacuolization in rats exposed chronically by inhalation (Dutertre-
Catella 1976), and increased incidence of coagulative necrosis and
hepatocytomegaly in male mice exposed chronically by gavage at 250 and 500
mg/kg/day (NTP 1986). The decreased liver weight in rats exposed by
inhalation is of questionable toxicological significance because
histological examination of a limited number of rats in the study did not
reveal treatment-related liver lesions. The toxicological significance of
the microvacuolization observed in liver cells of rats and rabbits is also
unknown. The liver lesions observed in male mice in the oral study were not
observed in female mice, but the reason for the sex difference is not known.
The mechanism by which isophorone produces liver lesions in male mice is not
known, but liver lesions are common in aged mice; isophorone may enhance an
age-related process. It is not known whether isophorone causes liver
effects or enhances age-related processes in humans.
Subchronic inhalation studies of isophorone (Smyth and Seaton 1940;
Smyth et al. 1942) reported severe kidney damage in rats and guinea pigs,
but these studies have been criticized for using impure isophorone and for
overestimating the exposure concentration (Rowe and Wolf 1963). Because of
these reports, however, NTP (1986) examined the kidneys twice and used
special staining techniques to confirm the lack'of histopathological lesions
and protein droplets in the kidneys of rats and mice exposed subchronically
to isophorone by gavage. Although the NTP (1986) study did not detect
protein droplet formation in the kidneys of rats or mice treated with
isophorone (Bucher 1988), protein droplets were found in the kidneys of male
rats exposed by inhalation to dihydroisophorone (Hazleton Labs 1968), a
metabolite of isophorone. Furthermore, Strasser (1988) found that
isophorone and its metabolites, dihydroisophorone and isophorol, induced
significant protein droplet formation in the kidneys of male rats treated
acutely by gavage. It was not clear if the response was dose-related.
Isolation and analysis of alpha  2µ-globulin from the kidney cytosol of rats
treated with isophorone or dihydroisophorone positively identified
isophorone or dihydroisophorone, respectively, in the  alpha  2µ--globulin samples,
Following treatment with isophorol, samples, isophorone was found in the alpha   2µ-
globulin indicating that isophorol was metabolized to isophorone. The
results of Strasser (1988) are preliminary and require confirmation, but the
data suggest that isophorone and its metabolites bind to alpha   2µ--globulin and
induce protein droplet nephropathy in male rats.
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alpha   2µ-Globulin is a low molecular weight protein synthesized in large
quantities in the male rat liver, secreted into the blood under the
influence of testosterone (Alden 1986), and filtered through the
glomerulus. The alpha   2µ-globulin is reabsorbed by the tubule cells and sequestered
into lysosomes, where it is catabolized into amino acids and peptides. In the
normal rat kidney, the rate of catabolism of alpha   2µ-globulin is relatively slow
compared with that of other proteins (Swenberg et al. 1989). In the male F344
rat, protein droplet nephropathy is characterized by accumulation of alpha   2µ-
globulin in lysosomes, degeneration and necrosis of tubular cells, formation
of granular casts, and regeneration (proliferation) of the tubular epithelium
(Swenberg et al. 1989). Chemicals that are known to induce protein droplet
nephropathy bind to alpha   2µ-globulin, yielding a complex that may be more
resistant to the proteolytic enzymes in the lysosomes, which leads to the
accumulation of the complex in the tubule cells.
alpha   2µ-Globulin has not been found in immature male rats, female rats, or
humans (Alden 1986). In adult male rats, the protein may function as a
pheromone carrier (Alden 1986). If isophorone induces nephropathy by the
suggested mechanism, the absence of alpha   2µ-globulin in humans raises the
question of the relevance to humans of the isophorone-induced kidney lesions
in male rats. alpha   2µ-Globulin is related to other low molecular weight
transport proteins that have been detected in humans (Swenberg et al. 1989),
but it is not known whether chemicals that are nephrotoxic to the rat will
bind to the human proteins or produce similar effects in humans.
In the chronic gavage study by NTP (1986), dosed male rats had
increased incidences of renal tubular cell hyperplasia, epithelial cell
hyperplasia of the renal pelvis, and tubular mineralization. The male rats
also had increased incidences of renal tubular cell tumors. The hyperplasia
of the tubular cells, therefore, may represent a preneoplastic response (see
discussion of cancer below). These proliferative kidney lesions were not
observed in male or female mice or in female rats. The mechanism for the
induction of proliferative kidney lesions may also be related to alpha   2µ-globulin-
induced nephropathy (see discussion of cancer below), again raising the
question of the relevance of the proliferative kidney lesions in male rats to
humans. This issue is presently the subject of scientific
investigation.
Female rats had increased incidences of age-related nephropathy (NTP
1986). The tubular mineralization in the male rats was coincident with
age-related nephropathies, which were more severe in the low-dose males. It
is possible, therefore, that isophorone treatment enhanced the age-related
nephropathies commonly seen in rats, but it is not known if isophorone could
enhance age-related processes in humans.
Neurological Effects. Humans occupationally exposed to isophorone at
levels as low as 5-8 ppm have complained of fatigue and malaise (Ware 1973).
When workroom levels were lowered to l-4 ppm, complaints ceased.








not known. Acute exposure of animals to high inhalation concentrations and 
oral and dermal doses affects the central nervous system as evidenced by 
such effects as narcosis, staggering, depression, ataxia, lethargy, and 
prostration and coma. No histologically detectable lesions have been found. 
in the brain, sciatic nerve, or spinal cord of animals exposed to isophorone 
by any route for any duration. Although not precisely known, the mechanism 
by which isophorone induces its neurological effects may involve 
interference with neuronal impulse transmissions via physical interaction of 
isophorone with nerve membrane components, as is seen with many organic 
solvents. The effects in animals at high exposures and the malaise and 
fatigue in humans at relatively low workroom concentrations of isophorone 
predict that exposure of humans to high air concentrations or high oral 
doses could result in severe central nervous system depression. 
 
Developmental Effects. Isophorone has been tested by inhalation for 
developmental effects in rats and mice. Evidence for intrauterine growth 
retardation was seen at an exposure concentration of 115 ppm (Bio/dynamics 
1984a,b). At 150 ppm, exencephaly was seen in several fetuses. While the 
incidence of this malformation was not statistically significant, it was 
seen in both species and only in treated animals. Dose-related maternal 
toxicity was evident in all treatment groups. Isophorone has not been 
tested for developmental effects by the oral or dermal route. No studies 
were located demonstrating that isophorone crosses the placenta in animals 
or in humans, but there is no reason to assume that it does not do so. It 
is not known whether isophorone could cause developmental effects in humans. 
 
Genotoxic Effects. No studies were located regarding the genotoxicity 
of isophorone in humans or animals by the inhalation, oral, or dermal 
routes. Isophorone has been tested for genotoxic effects in vitro and in 
mice treated intraperitoneally (Table 2-4). Isophorone was negative for 
reverse mutations with and without metabolic activation with S9 prepared 
from rat or hamster livers (NTP 1986). CMA (1984) reported that isophorone 
was negative both with and without metabolic activation in mouse lymphoma 
cells, while NTP (1986) found a weakly positive effect without activation in 
the same cell system. The concentrations of isophorone used by NTP (1986) 
were at least 60 times higher than those used by CMA (1984). Negative 
results were found for unscheduled DNA synthesis in rat hepatocytes, for 
chromosome aberrations in Chinese hamster ovary cells, and in the 
micronucleus test in mice (CMA 1984; NTP 1986). NTP (1986) found a positive 
response for sister chromatid exchange in Chinese hamster ovary cells in the 
absence, but not in the presence, of a metabolic activating system. 
 
In assessing the potential for a chemical to produce heritable 
mutations in humans, it is necessary to examine the weight of evidence 
obtained from in vitro tests for mutations in microorganisms and cultured 
mammalian cells, from in vivo tests of mutations in animals, and from in 
vitro and in vivo tests for chromosome aberrations in mammalian cells. The 
strongest evidence would come from the demonstration that a chemical causes 




located that tested isophorone in cultured human cells or examined the cells
of people with known exposure, this evidence is lacking. Of the five
experiments that tested whether isophorone caused mutations or chromosome
aberration in cultured mammalian cells, only two were positive: a weak
mutagenic response in mouse lymphoma cells and a positive test for sister
chromatid exchange in Chinese hamster ovary cells in the absence, but not
in the presence, of metabolic activation were obtained by NTP (1986).
Isophorone was not mutagenic in the Salmonella/microsome assay (NTP 1986).
The only in vivo test was the micronucleus test in mice, which was negative
(CMA 1984). Therefore, isophorone may be weakly genotoxic in mammalian
cells, but the evidence is insufficient to predict that isophorone poses a
genotoxic threat to humans.
Cancer. Increased incidences of relatively rare renal tubular cell
adenomas and carcinomas were observed in male rats, but the increases were
not statistically significant by the Fisher Exact test or the Cochran-
Armitage test (NTP 1986). When adjusted for mortality, however, the
increased incidences were significantly different from control in the highdose
males when analyzed by the Lifetable test and significant for dose-related
trend by the Lifetable and the Incidental Tumor tests. As the
kidney tumors were not fatal, the appropriateness of Lifetable test for the
analysis of these tumors is questionable. The overall unadjusted incidences
were significantly different from the historical control incidence by the
Fisher Exact test. The kidney tumors were not observed in female rats or in
male or female mice.
Isophorone is one of several diverse chemicals that have been found to
induce kidney tubular cell tumors in male rats, but not in female rats, male
or female mice, hamsters, guinea pigs, dogs, and nonhuman primates (Alden
1986; Swenberg et al. 1989). These chemicals include 1,4-dichlorobenzene,
dimethymethylphosphonate, JP-5 jet fuel; d-limonene, pentachloroethane,
tetrachloroethylene, and unleaded gasoline, which have also been found to
cause protein droplet nephropathy in male rats. As discussed above for
systemic renal effects, binding of these chemicals to alpha   2µ-globulin, a
protein that appears to be unique to male rats, is believed to be involved
in the protein droplet nephropathy. Based on tumor initiation-promotion
studies of trimethylpentane, an alpha   2µ-globulin binding component of unleaded
gasoline, and the body of data on alpha   2µ-globulin-induced protein droplet
nephropathy, the following mechanism has been proposed for the formation of
tumors in the male rat kidney (Swenberg et al. 1988). Accumulation of the
chemical alpha   2µ-globulin complex causes lysosomal protein overload and necrosis
of the cells, with subsequent cellular regeneration that continues as long
as the rat is exposed to the chemical and produces alpha   2µ-globulin. The
increased cellular proliferation may promote tumorigenesis by increasing
the number of cells in the kidney that have undergone spontaneous
initiation. Given the findings of Strasser (1988) that isophorone was
associated with alpha   2µ-globulin and induced protein droplet formation in the
kidneys of male rats and that cell proliferation may be involved in the
mechanism of male rat kidney tumorigenesis, the finding in the NTP (1986)
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study of increased incidences of tubular epithelial hyperplasia in addition
to the increased incidences of tubular cell tumors is consistent with the
mechanism proposed by Swenberg et al. (1989).
As discussed above, alpha   2µ-globulin appears to be unique to male rats. If
isophorone induces kidney tumors solely by the suggested mechanism, the
absence of alpha   2µ-globulin in humans raises the question of the relevance to
humans of the isophorone-induced kidney tumors in male rats. Although alpha   2µ
globulin is related to other low molecular weight transport proteins that
have been detected in humans (Swenberg et al. 1989), it is not known whether
chemicals that produce kidney tumors in male rats bind to the human proteins
or produce similar effects in humans. This issue is currently being
reviewed by the EPA.
Male rats treated with isophorone in the NTP (1986) study also had
preputial gland carcinomas, an extremely rare finding. Analogous tissues
in humans are modified sebaceous glands in the prepuce (foreskin of the
penis), but it is not known whether isophorone could cause tumors in these
glands or other glandular tissues in humans.
In male mice, significant dose-related trends by the Cochran-Armitage
test were found for hepatocellular adenoma and carcinoma (combined) and for
fibromas, sarcomas, fibrosarcomas, and neurofibrosarcomas (combined) of the
integumentary system. These incidences were increased significantly above
control rates in the high-dose males by the Incidental Tumor and Fisher
Exact tests. Low-dose male mice had significantly increased incidences of
lymphoma compared with controls by the Life Table test and Fisher Exact
test, but the tests for dose-related trend were not significant because the
incidence in high-dose male mice was lower than the incidence in low-dose
male mice. This evidence was considered equivocal by NTP (1986), and it is
not known whether exposure to isophorone would cause cancer in human.
2.4 LEVELS IN HUMAN TISSUES AND FLUIDS ASSOCIATED WITH HFALTH EFFECTS
No studies were located regarding levels of isophorone or its
metabolites in human tissues and fluids associated with effects.
Furthermore, no studies were located describing methods for detecting
isophorone or its metabolites in human tissues and fluids.
2.5 LEVELS IN THE ENVIRONMENT ASSOCIATED WITH LEVELS IN HUMAN TISSUES AND/OR
HEALTH EFFECTS
Although isophorone has been detected in environmental media (see
Chapter 5), no data were located allowing associations of effects of
isophorone in humans or levels of isophorone or its metabolites in human












2.6.1.1 Inhalation Exposure 
 
No studies were located regarding the rate and extent of absorption of 
isophorone following inhalation exposure of humans or animals to isophorone. 
Isophorone was widely distributed to the organs of rats exposed for 4 hours 
to a concentration of 400 ppm isophorone (Dutertre-Catella 1976), 
indicating that isophorone is absorbed after inhalation exposure. That 
isophorone is absorbed by the lungs can also be inferred from the systemic 
toxicity observed in animals following inhalation exposure (see Section 
2.2.1.2 on systemic effects following inhalation exposure). Imbriani et al. 
(19'85) measured a blood/air partition coefficient of 2349 for isophorone, 
indicating that isophorone is absorbed readily from the lungs. 
 
2.6.1.2 Oral Exposure 
 
No studies were located regarding the absorption of isophorone in 
humans following oral exposure. 
 
Preliminary results of a pharmacokinetic study indicate that rats 
treated orally with 14C-isophorone excreted 93% of the radiolabel in the 
urine, expired air, and feces in 24 hours (Strasser 1988). The majority was 
found in the urine indicating that isophorone was well absorbed. The wide 
distribution of isophorone in the organs of rats and a rabbit l-5 hours 
after dosing by gavage with 4000 mg/kg (Dutertre-Catella 1976) indicates 
rapid gastrointestinal absorption. In two rabbits given a gavage dose of 
1000 mg/kg isophorone, a blood level of isophorone of 102 µg/L was found 
within 10 minutes. The level increased to 141 µg/L in 30 minutes and 
declined to ≤0.05 µg/L in 21 hours. The results indicate rapid absorption 
and elimination. The detection of unchanged isophorone and its metabolites 
(see Section 2.6.3 on Metabolism) in the urine and the observations of . 
systemic toxicity and carcinogenicity (see Section 2.2.2 on effects of oral 
exposure) in animals exposed orally to isophorone provide qualitative 
evidence that isophorone is absorbed after oral exposure. 
 
2.6.1.3 Dermal Exposure 
 
No studies were located regarding the absorption of isophorone 
following dermal exposure of humans or animals. A report that a high dermal 
dose resulted in signs of CNS depression in l/4 rabbits suggests that 
isophorone is absorbed dermally (Hazleton Labs 1964), but other systemic 
effects have not been described. 
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2.6.2.1 Inhalation Exposure 
 
No studies were located regarding the distribution of isophorone 
following inhalation exposure of humans. 
 
In rats exposed to 400 ppm isophorone for 4 hours and sacrificed 
immediately after exposure or 1.5 or 3 hours after exposure, levels of 
isophorone were highest in all tissues examined (brain, lungs, heart, 
stomach, liver, spleen, pancreas, kidney, adrenals, testicles, and ovaries) 
immediately after exposure (Dutertre-Catella 1976). Levels ranged from 1.5 
to 74 µg/g tissue wet weight. The levels dec1ine.d rapidly in males but 
declined very little in females by 3 hours after exposure. 
 
2.6.2.2 Oral Exposure 
 
No studies were located regarding the distribution of isophorone in 
humans following oral exposure. 
Radiolabel was widely distributed in male rats 24 hours after an oral 
dose of 14C-isophorone in corn oil, with highest levels in the liver, 
kidney, preputial gland, testes, brain, and lungs (Strasser 1988). 
Isophorone was widely distributed to the tissues of rats and a rabbit 
following treatment with isophorone at a gavage dose of 4000 mg/kg 
(Dutertre-Catella 1976). The rats died within 1-5 hours and the rabbit 
died within an hour after dosing at which times the tissues were sampled for 
analysis. In rats, tissue levels of isophorone in µg/g tissue wet weight 
were as follows: stomach - 6213, pancreas - 2388, adrenals - 1513, spleen - 
1038, liver - 613, brain - 378, lung - 383, heart - 387, kidney - 465, 
testes - 275, and ovaries - 471. In the rabbit, tissue levels were as 
follows: stomach - 5395, adrenals - 1145, ovaries - 3000, spleen - 545, 
liver - 515, kidney - 295, heart - 260, and lungs - 50. 
 
2.6.2.3 Dermal Exposure 
 
No studies were located regarding the distribution of isophorone 




No studies were located regarding the metabolism of isophorone in 
humans following exposure to isophorone by any route. 
 
Rabbits and rats treated orally with isophorone excreted unchanged 
isophorone in the expired air and in the urine (Dutertre-Catella et al. 
1978; Truhaut et al. 1970). The urine also contained 3-carboxy-5,5- 
dimethyl-2-cyclohexene-l-one and glucuronic conjugates of 3,3,5-trimethyl-2- 








(dihydroisophorone), and cis- and trans-3,5,5 trimethylcyclohexanols. Rat 
urine contained more dihydroisophorone and less isophorol than did rabbit 
urine. Dutertre-Catella et al. (1978) proposed that metabolism of 
isophorone involves methyloxidation to 3-carboxy-5,5-dimethyl-2- 
cyclohexene-l-one, reduction of the ketone group to isophorol, reduction'of 
the ring double bond to dihydroisophorone, and dismutation of 
dihydroisophorone to cis- and trans-3,5,5-trimethylcyclohexanols. The 




2.6.4.1 Inhalation Exposure 
 
No studies were located regarding the excretion of isophorone or its 
metabolites following inhalation exposure of humans to isophorone. 
Dutertre-Catella (1976) found that the excretion of isophorone in air was 
low (110 µg) and declined further to 30 µg at 2.5-3 hours after exposure of 
rats to 400 ppm for 4 hours. 
 
2.6.4.2 Oral Exposure 
 
No studies were located regarding the excretion of isophorone or its 
metabolites following oral exposure of human to isophorone. 
Rats and rabbits excreted unchanged isophorone and metabolites in the 
urine and unchanged isophorone in the expired air following oral dosing with 
isophorone (Dutertre-Catella et al. 1978), but the rate and extent of 
excretion were not reported. Preliminar results of a pharmacokinetic study 
indicate that following an oral dose of 14C-isophorone, male rats excreted 93% 
of the radiolabel in the urine, feces, and expired air in 24 hours, with the 
majority in the urine (Strasser 1988). 
 
2.6.4.3 Dermal Exposure 
 
No studies were located regarding the excretion of isophorone or its 
metabolites following dermal exposure of humans or animals. 
 
2.7 INTERACTIONS WITH OTHER CHEMICALS 
 
The possible synergistic interactions of isophorone with other 
solvents are important because mixed exposures occur in occupational 
settings and may occur in the environment. The joint toxicity of isophorone 
with 26 other industrial liquid chemicals based on determinations of the 
oral LD5Os in rats of each chemical alone and in a 1:l (v/v) mixture was 
determined (Smyth et al. 1969). The LD5Os of the mixtures were predicted 
based on the assumption of additivity of the LD5Os of each component, and 
the ratios of the predicted values to experimentally determined values were 
calculated. Greater than additive toxicity was observed for the mixtures of 









morpholine, ethyl alcohol, ethyl acetate, carbon tetrachloride, 
acrylonitrile, acetonitrile, and acetone. Less than additive toxicity was 
observed for the mixtures of isophorone with 17 chemicals: Ucon LB-250, 
Ucon 50-HB-260, toluene, Tergitol XD, propylene oxide, polyethylene glycol 
200, Phenyl Cellosolve, nitrobenzene, acetophenone, aniline, Butyl 
Cellosolve, butyl ether, diethanolamine, dioxane, ethyl acrylate, ethylene 
glycol I and formalin. When the frequency distribution of the ratios for all 
combinations of all chemicals were adjusted to give a normal distribution, 
however, none of the ratios for mixtures with isophorone deviated 
significantly from the mean ratios, indicating essentially additive 
toxicity. In a subsequent study, the additivity of equitoxic mixtures, 
defined as a mixture of chemicals in volumes directly proportional to their 
oral LD50 in rats, was determined (Smyth et al. 1970). Isophorone showed 
less than additive toxicity with Phenyl Cellosolve and Ucon Fluid 50-HB-260, 
and greater than additive toxicity with propylene oxide. The mechanism for 
such interactions is not known. 
 
2.8 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
 
Isophorone produced kidney effects in male rats in the NTP (1986) 
study. Strasser (1988) found that isophorone caused protein droplet 
formation in the kidneys of male rats, suggesting that isophorone can 
induce protein nephropathy. Alden (1986) discussed the possibility that 
proteinuric humans and humans with low molecular weight protein nephropathy, 
such as people with multiple myeloma (Bence-Jones protein) or mononuclear 
cell leukemia (lysozyme), may be more susceptible to chemically-induced 
protein nephropathy. He concluded, however, that this syndrome is probably 
specific to the male rat. 
 
2.9 ADEQUACY OF THE DATABASE 
 
Section 104 (i) (5) of CERCLA, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the 
Public Health Service) to assess whether adequate information on the health 
effects of isophorone is available. Where adequate information is not 
available, ATSDR, in cooperation with the National Toxicology Program (NTP), 
is required to assure the initiation of a program of research designed to 
determine these health effects (and techniques for developing methods to 
determine such health effects). The following discussion highlights the 
availability, or absence, of exposure and toxicity information applicable to 
human health assessment. A statement of the relevance of identified data 
needs is also included. In a separate effort, ATSDR, in collaboration with 
NTP and EPA, will prioritize data needs across chemicals that have been 
Profiled. 
 
2.9.1 Existing Information on Health Effects of Isophorone 
 
As seen from Figure 2-4, very little information is available 









Experimental studies in humans have attempted to determine the inhalation 
thresholds for odor detection and eye, nose, and throat irritation. Reports 
on humans occupationally exposed to isophorone also indicate that isophorone 
is irritating to the skin, eye, nose, and throat, and may cause symptoms of 
dizziness, fatigue, and malaise. 
 
Data are available for acute and intermediate inhalation exposures 
that have resulted in death of animals. These exposures also produced 
signs of central nervous system toxicity, lung irritation, possible kidney 
damage, and possible hematological changes and growth depression. Chronic 
inhalation exposure of rats and rabbits resulted in mild liver effects. 
Inhalation exposure of pregnant rats and mice during gestation did not 
result in fetotoxic or teratogenic effects at concentrations up to 115 ppm, 
but results at 150 ppm are difficult to interpret. No information was 
available on the effects of chronic inhalation exposure. 
 
Data are available for oral doses associated with death and increased 
mortality in acute, intermediate, and chronic exposure. Acute and 
intermediate oral studies have also produced signs of central nervous system 
toxicity at high doses during exposure. In intermediate duration studies of 
oral exposure of animals to isophorone, comprehensive histological 
examination of tissues and organs found no effects. Chronic oral exposure 
of mice resulted in hyperkeratosis of the forestomach, non-neoplastic liver 
lesions, and equivocal evidence of liver tumors, integumentary system 
tumors, and malignant lymphomas. Chronic oral exposure of rats resulted in 
hyperplastic and neoplastic kidney lesions and preputial gland carcinomas. 
 
Application of isophorone to the skin of animals results in skin 
irritation, and application to the eye results in severe eye damage. There 
is some information that dermal exposure of rabbits causes signs of 
neurotoxicity at high doses. This could indicate that isophorone is 
absorbed dermally, but other systemic effects have not been described. 
 
No studies of the genotoxic effects of oral, inhalation, or dermal 
exposure to isophorone were found, but studies in bacteria and mammalian 
cells indicate that isophorone is at best weakly genotoxic. 
 
2.9.2 Data Needs 
 
Single Dose Exposure. Studies of single inhalation, oral, or dermal 
exposure of rats, guinea pigs, and mice have provided data on lethal and 
non-lethal levels of isophorone and levels producing signs of neurotoxicity. 
Single-dose dermal and ocular studies in animals have demonstrated that 
isophorone is irritating to the skin and eyes. Gross clinical and necropsy 
observations have been made, but no reliable single-dose study examined the 
internal tissues of animals histologically or attempted to identify 
doseresponse data for more subtle systemic toxic effects, Such studies might 








well as information on the thresholds for systemic toxicity due to single 
dose exposure. 
 
Repeated Dose Exposure. Repeated inhalation exposure studies of 
isophorone conducted in rats and guinea pigs by Smyth et al. (1942) 
reported severe respiratory and kidney lesions, but this study was 
criticized by Rowe and Wolf (1963) for using impure isophorone and 
overestimating the concentrations. Furthermore, dose-response data were 
poorly reported and results in rats and guinea pigs were reported together. 
A study by Hazleton Labs (1968) suggested hematological and liver weight 
effects in rats, but only one exposure concentration was used. A 4-6 month 
inhalation study in rats reported ocular and nasal irritation but no 
exposure-related effects on lungs or livers (Dutertre-Catella 1976). 
Results were poorly reported and only one concentration was used. A 
wellconducted subchronic inhalation study that uses several concentrations of 
pure isophorone and monitors for clinical signs, hematological and 
biochemical changes, and gross and histopathological changes in animals 
would provide dose-response data for toxicological endpoints and remove 
uncertainties associated with the study by Smyth et al. (1942). Wellconducted, 
repeated-dose oral studies in rats, mice, and dogs at several 
dosage levels including maximum tolerated doses produced no systemic 
effects. A 2-week dermal study in rabbits revealed no biochemical evidence 
of liver damage (Dutertre-Catella 1976), but other indices of toxicity were 
not examined. An a-week dermal study in rats revealed erythema and scar 
tissue formation, which disappeared after exposure ceased (Dutertre-Catella 
1976). As screen printers are repeatedly exposed dermally to isophorone and 
the extent of dermal absorption is not known, better repeated dermal dose 
studies examining systemic toxicity in animals might provide information on 
whether repeated dermal exposure of humans poses a threat of toxic 
potential. 
 
Chronic Exposure and Carcinogenicity. Well-conducted chronic oral 
studies provide information on the systemic and carcinogenic effects of 
isophorone in rodents. In a chronic oral study, male rats exposed to 
isophorone developed kidney and preputial gland tumors. The relevance of 
these tumors in male rats to humans has been questioned; therefore, 
additional research to clarify the relevance is desirable. Indeed, on-going 
studies are being conducted (see Section 2.9.3). In a chronic inhalation 
study, rats and rabbits had ocular and nasal irritation and slight liver 
effects (Dutertre-Catella 1976), but few animals and only one concentration 
were used. No chronic dermal studies were located. It is not possible to 
predict that effects following chronic inhalation or dermal exposure to 
isophorone would be similar to those following chronic oral exposure, 
partially because the pharmacokinetic disposition of isophorone has not been 
compared for the three routes of exposure. Available toxicokinetic data 
(see Section 2.6) indicate that isophorone is metabolized to 
dihydroisophorone, isophorol, and other products after oral dosing of rats 
and rabbits, but different metabolic pathways may operate following 








distribution among the three routes of exposure could also account for 
differences in toxic response. Chronic inhalation and dermal studies in 
animals might provide dose-response data on the systemic effects that could 
be related to possible systemic effects of inhalation and dermal exposure of 
humans. Long-term exposure of humans to isophorone by inhalation and by 
skin contact occurs in occupational settings. 
 
Genotoxicity. The available genotoxicity studies (Salmonella/microsome 
assays, mutations in mouse lymphoma cells, tests of unscheduled DNA 
synthesis, sister chromatid exchange, and chromosome aberrations in cultured 
mammalian cells, and an in vivo micronucleus tests) indicate that isophorone 
may be weakly genotoxic. Additional genotoxicity tests would add to the 
rather limited data base on genotoxicity, but probably would not change the 
conclusion that isophorone in weakly genotoxic. 
 
Reproductive Toxicity. An intermediate duration study examined only 
the pregnancy rate and litter size in rats exposed to isophorone by 
inhalation for 3 months before mating. Histological examination of 
reproductive organs of rats, mice, and dogs exposed orally to isophorone in 
subchronic and chronic studies indicate no treatment-related lesions, but 
multigeneration or continuous breeding studies have not been conducted. 
Such studies would provide further information regarding the reproductive 
effects of isophorone in animals, which may then be related to possible 
reproductive effects in humans. 
 
Developmental Toxicity. Developmental studies by the inhalation route 
in rats indicated growth retardation in the rat fetuses at a concentration 
of 115 ppm, and maternal toxicity at all concentrations tested (≥25 ppm). 
Exencephaly was seen in several rat and mouse fetuses after exposure of the 
dams to 150 ppm during the organogenesis period. The developmental effects 
following oral or dermal exposure have not been studied. It is not known 
whether isophorone crosses the placenta, but there is no reason to assume 
that it would not do so. Further developmental studies in animals by 
relevant environmental routes, such as drinking water and diet, would 
provide information on possible fetotoxic and teratogenic effects in animals 
that might be relevant to humans. Studies in drinking water and diet are 
particularly relevant because isophorone has been detected in groundwater, 
ambient water, drinking water, oysters, and cranberries (see Section 5.4 on 
environmental monitoring). 
 
Immunotoxicity. No histopathological effects on immunological organs 
and tissues of animals were found in subchronic and chronic oral studies, 
but a battery of immunotoxicity tests has not been performed. Such tests 
provide a more sensitive assessment of possible immunotoxic effects than do 
histological examinations of tissues and organs of the immunological system. 
Isophorone is a skin irritant in rabbits, guinea pigs, and humans, but it 
has not been tested for sensitization. Such tests might provide information 








dermal contact by humans occurs in occupational settings and in soil at 
waste sites. 
 
Neurotoxicity. No histopathological effects on organs and tissues of 
the neurological systems of animals were found in subchronic and chronic 
oral studies, but signs of central nervous system toxicity were reported in 
inhalation, oral, and dermal studies. A battery of tests for neurotoxicity 
would provide further information of the neurotoxicity in animals, which 
then might be related to possible neurotoxic effects in humans. 
Epidemiological and Human Dosimetry Studies. The only known health 
effects of isophorone in humans are eye, nose, and throat irritation, and 
fatigue and malaise. This information comes from two limited industrial 
hygiene surveys, two experimental studies in human volunteers, and a 
communication to the ACGIH. Effects in animals, however, include CNS 
depression, liver and kidney damage, hyperkeratosis of the forestomach, some 
evidence of cancer, and suggestive evidence of developmental toxicity. As 
discussed in Chapter 5, isophorone has been detected in surface water, 
drinking water, industrial effluents, urban runoff, and water and soil at 
waste sites. Isophorone has a relatively low vapor pressure (Union Carbide 
1968) and high reactivity with hydroxyl radicals (Atkinson 1985, 1987); 
therefore, exposure to isophorone in the ambient atmosphere distant from the 
source is unlikely. Indeed, monitoring data for isophorone in air are 
lacking. Inhalation as well as dermal exposure, however, occurs in 
occupational settings where isophorone is used as a solvent. Epidemiology 
studies of people who live in areas where isophorone has been detected in 
ambient and drinking water, near industries releasing isophorone, or near 
hazardous waste sites, and of people occupationally exposed, could provide 
information on whether isophorone produces effects in humans similar to 
those seen in animals, or other toxic effects. 
 
No studies were located that monitored human tissues for isophorone or 
its metabolites. Furthermore, analytical methods for the detection of 
isophorone or its metabolites in humans tissues and fluids were not located. 
Metabolism studies in rats and rabbits, however, indicated that isophorone, 
isophorol, dihydroisophorone, 3-carboxy-5,5-dimethyl-2-cyclohexene-l-one, 
and cis- and trans-3,5,5-trimethylcyclohexanols were excreted in the urine 
following oral exposure to isophorone (Dutertre-Catella et al. 1978). If 
isophorone and these or other metabolites can be detected in the urine of 
humans and be correlated with exposure, it may be possible to monitor humans 
for exposure. If toxic effects of isophorone are identified in humans, it 
may then be possible to correlate urinary levels of isophorone or its 
metabolites with systemic effects. 
 
Biomarkers of Disease. No disease states in humans produced by 
exposure to isophorone are known. If epidemiological studies are conducted 
that correlate exposure with diseases, it may be possible to identify subtle 








Disease Registries. At present, the only known health effects of 
isophorone in humans are eye, nose, and throat irritation, and fatigue and 
malaise. If epidemiological studies identify particular diseases produced 
by isophorone, it may be possible to determine the number of people affected 
and the factors associated with identifying the disease in certain 
populations, such as exposure to high levels near hazardous waste sites. 
 
Bioavailability from Environmental Media. No studies were located 
regarding the bioavailability of isophorone from environmental media. 
Furthermore, no reports were located indicating that isophorone or its 
metabolites have been detected in human tissues or fluids. Since the 
monitoring literature reports that isophorone is present in the environment 
as well as in environmental organisms, the lack of data does not 
necessarily indicate a lack of bioavailability. Fish may be the only source 
of isophorone in the environment that is not subject to large spatial and 
temporal variations in concentration, as appears to be the case with 
drinking water. In particular, fish in the Lake Michigan area are known to 
contain isophorone (Camanzo et al. 1987), and analysis of the body fluids of 
people who consume the fish may allow a determination of the existence of 
exposure and an estimation of the degree of exposure. 
 
Food Chain Bioaccumulation. No studies were located regarding the 
food chain bioaccumulation of isophorone from environmental media. The 
monitoring literature reports that isophorone is present in the environment 
as well as in environmental organisms. The monitoring data further suggest 
that isophorone levels in fish do not correlate well with the lipid content 
of the fish (see Section 5.4). Thus, structure-activity relationships 
developed to estimate levels in biological media based on the partitioning 
properties of a chemical may not provide accurate information for 
isophorone. Furthermore, only one bioaccumulation study was available. In 
this study, which indicated a low potential for bioaccumulation, fish were 
exposed to isophorone in water rather than in food. From these data, it 
appears that food chain bioaccumulation may be occurring, and a clearer 
understanding of the potential for this would aid in determining how levels 
in the environment affect the food chain and potentially impact on human 
exposure levels. 
 
Absorption, Distribution, Metabolism, Excretion. The only 
toxicokinetic data of isophorone are the in vivo metabolism studies in rats 
and rabbits following oral exposure (Dutertre-Catella et al. 1978) and the 
preliminary disposition data of Strasser (1988). These studies indicate 
that isophorone is metabolized to dihydroisophorone and isophorol in animals 
following oral exposure. Different metabolic pathways and patterns of 
distribution and excretion, however, may operate after inhalation or dermal 
exposure. Differences in the rate and extent of absorption, metabolic 
pathways, and disposition may account for differences in the toxicity of a 
chemical following exposure by different routes. Thus, further studies in 
animals of the rate and extent of absorption and excretion following 
exposure by all three routes and of distribution and metabolism following 
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inhalation and dermal exposure, and in vitro studies to elucidate metabolic
pathways would provide the information to fully characterize the
pharmacokinetics of isophorone in animals. Ethical considerations limit the
testing of humans, but the determination of the urinary excretion of
isophorone and its metabolites by humans with known exposure to isophorone
(e.g., workers in the printing trades), may provide a means of monitoring
humans for exposure.
Comparative Toxicokinetics. The metabolism studies by Truhaut et al.
(1970) and Dutertre-Catella et al. (1978) indicated that metabolism of
isophorone in rats and rabbits was qualitatively similar, but the proportion
of the metabolites excreted was different. Differences in the
toxicokinetics of a chemical among species may account for differences in
toxic responses. The potential for isophorone to produce toxic effects has
been investigated in rats, mice, dogs, guinea pigs, and rabbits, but the
animal species that serves as the best model for extrapolating results to
humans is not known. Ethical considerations limit the amount of information
that can be obtained by testing isophorone in humans, but analysis of the
urine of people with known exposure to isophorone for parent compound or
metabolites could provide knowledge of the metabolic pathways in humans.
Qualitative and quantitative comparison of human metabolites with those of
animals could help identify the most appropriate species to serve as a model
for predicting toxic effects in humans and studying the mechanisms of
action.
2.9.3 On-going Studies
A manuscript of the study demonstrating protein droplet formation in
the kidneys of male rats following acute oral exposure to isophorone and of
the distribution study by Strasser will be submitted for publication to
Toxicology and Applied Pharmacology (Strasser 1988). These studies were
presented as a Poster Presentation at the Society of Toxicology meetings in
February, 1988, and an abstract (Strasser et al. 1988) has been published.
In addition, the manuscript to be submitted to Toxicology and Applied
Pharmacology will contain added information on the distribution of
radiolabel in female rats and in the preputial gland of male rats (Strasser
1988).
James Swenberg, formerly at the Chemical Industry Institute of
Toxicology (CIIT), and his colleagues at CIIT are continuing the
investigation of the mechanism of hydrocarbon-induced nephropathy and the
induction of renal tumors in male rats (Swenberg et al. 1989). These
investigations include isophorone. Swenberg and colleagues are also
investigating whether low molecular weight proteins found in humans behave
similarly to alpha 2µ-globulin of male F344 rats.
No on-going biomonitoring studies or studies of toxic effects of









3.1 CHEMICAL IDENTITY 
 
Data pertaining to the chemical identity of isophorone are listed in 
Table 3-l. 
 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 
 














According to the most recent edition of the United States 
International Trade Commission publication on U.S. production and sales of 
synthetic organic chemicals (USITC 1987), Union Carbide (Institute, WV), is 
the only domestic manufacturer of isophorone. A comparison of the list of 
isophorone manufacturers in USITC (1987) and USITC (1986) shows that Exxon 
Corporation (Bayway, NJ) also manufactured this chemical, but discontinued 
production in 1985. Because of the limited number of domestic manufacturers 
of isophorone and their desire to maintain confidentiality, up-to-date 
information regarding the production volume of isophorone in the U.S. is not 
available. In 1973, 35 million pounds of isophorone were produced in the 
United States (Papa and Sherman 1981) and in 1980, approximately 20-30 
million pounds were produced (CMA 1981). The decrease may be because of 
replacement of isophorone with less costly solvents (CMA 1981). 
 
Isophorone can be prepared by (1) passing acetone vapor over a 
catalyst bed of magnesium aluminate, zinc oxide-bismuth oxide, or calcium 
oxide under pressure at 300-400°C or (2) reacting acetone, water (up to 
30%), and potassium hydroxide (≅1%) in a column under a pressure of about 35 
atm and at a temperature of about 200°C (Papa and Sherman 1981). Commercial 
isophorone usually contains some unconjugated isomer (up to 5%) and small 
amounts (<l%) of xylitone (Papa and Sherman 1981). Isophorone tends to 
discolor on prolonged storage; stabilization against color formation can be 
provided by treatment with p-toluenesulfonic acid, acidified Fuller's earth, 




During 1984, 2,158 million pounds of isophorone were imported into the 




Isophorone is a solvent for a large number of natural and synthetic 
polymers, resins, waxes, fats, and oils. Specifically, it is used as a 
solvent for concentrated vinyl chloride/acetate-based coating systems for 
metal cans, other metal paints, nitrocellulose finishes, printing inks for 
plastics, some herbicide and pesticide formulations, and adhesives for 
plastics, poly(viny1) chloride and polystyrene materials (Papa and Sherman 
1981). Isophorone also is an intermediate in the synthesis of 3,5-xylenol, 
3,3,5-trimethylcyclohexanol (Papa and Sherman 1981), and plant growth 
retardants (Haruta et al. 1974). Of the total production, 45-65% is used in 
vinyl coatings and inks, 15-25% in agricultural formulations, 15-30% in 











Isophorone may be disposed of by incineration, wastewater treatment, or 
sanitary landfill (OHM-TADS 1988). 
 
4.5 ADEQUACY OF THE DATABASE 
 
Section 104 (i) (5) of CERCLA, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the 
Public Health Service) to assess whether adequate information on the health 
effects of isophorone is available. Where adequate information is not 
available, ATSDR, in cooperation with the National Toxicology Program (NTP), 
is required to assure the initiation of a program of research designed to 
determine these health effects (and techniques for developing methods to 
determine such health effects). The following discussion highlights the 
availability, or absence, of exposure and toxicity information applicable to 
human health assessment. A statement of the relevance of identified data 
needs is also included. In a separate effort, ATSDR, in collaboration with 
NTP and EPA, will prioritize data needs across chemicals that have been 
profiled. 
 
4.5.1 Data Needs 
 
Production, Use, Release, and Disposal. Industrial production methods 
for isophorone are well described in the literature (including the patent 
literature) and there does not appear to be a need for further information 
in this area. Uses of isophorone are documented, but a recent detailed 
breakdown of the percentage of production consumed by each use category is 
lacking. There is also a lack of data regarding the presence of isophorone 
in retail products, such as paints and paint thinners. This information, 
which is useful for estimating the potential for environmental releases from 
various industries as well as the potential environmental burden, is 
difficult to obtain in detail since it is considered confidential business 
information for those industries that manufacture isophorone. Release 
information is similar to use information in that it is not easily obtained 
and can be used to estimate environmental burdens and potentially exposed 
populations. According to the Emergency Planning and Community Right to 
Know Act of 1986 (EPCRTKA), ((313), (Pub. L. 99-499, title III, (313), 
industries are required to submit release information to the EPA. The Toxic 
Release Inventory (TRI), which contains release information for 1987, became 
available in May of 1989. This database will be updated yearly and should 
provide a more reliable estimate of industrial production and emission, 
Disposal information is useful for determining environmental burden and 
potential sources of high environmental exposures. There is a lack of data 
on current disposal practices for this chemical. 
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5.1 OVERVIEW
Isophorone is released to the air mainly in urban centers, as a result
of evaporation of solvents containing this chemical. Isophorone can enter
surface waters from industrial effluent discharges or from runoff from soils
at hazardous waste or other contaminated sites. Isophorone disappears
rapidly in air by hydroxyl radical reaction (half-life <5 hours), but may
persist in natural waters from several days to about a month.
Volatilization and sorption are not expected to be significant removal
mechanisms from water. In soils, isophorone is expected to degrade
microbially, but no rate data are available. Isophorone has been monitored
in effluents (range <5-1380 ppb), ambient water (range <0.6'-100 ppb),
drinking water (from contaminated surface water) (range 0.02-9.5 ppb), and
soils at hazardous waste sites (range 0.16-6500 ppm). At this time,
isophorone has been found in at least 9 out of 1177 National Priority List
(NPL) hazardous waste sites in the United States (VIEW database 1989).
Occupational exposures occur mainly by inhalation and dermal contact and are
documented most frequently in the printing trades. Air concentrations in
screen printing facilities range from <0.47-25.7 ppm. A 1988 estimate by
the National Institute for Occupational Safety and Health reported that
37,469 workers (9211 of whom were female) were exposed to isophorone in both
trade name products and chemical named products.
5.2 RELEASES TO THE ENVIRONMENT
5.2.1 Air
Since isophorone is used mainly as a solvent (see Subsection 4.3) that
is evaporated during or after use, the vast majority of environmental
releases are to the air. Use patterns indicate that most air releases are
in urban centers, with a smaller percentage of release in rural areas.
Nonetheless, very little ambient air monitoring data exist to confirm this,
probably because of its short atmospheric lifetime (half-life <5 hours).
Apparently, a major source of isophorone in the environment is the printing
industry, since these operations usually do not use emission control
technologies to reduce emitted isophorone concentrations (Bierbaum and
Parnes 1974; Kominsky 1981; Lee and Frederick 1981; Samimi 1982). Other
industries e.g. metal coating that use similar ventilation methods (NIOSH
1978a) are major sources of atmospheric isophorone. Coal-fired power plants
may also emit isophorone to the air, since isophorone has been detected in
the fly ash of one such plant (Harrison et al. 1985).
Volatilization from surface waters is not expected to be a significant
source of isophorone in the atmosphere, since this is anticipated to be-?
slow process (based on the Henry's Law Constant of 4.55~10~~ atm m3 mol ).








water to the air, particularly if gas stripping methods are used (Hawthorne 
and Sievers 1984, Hawthorne et al. 1985). Drinking water plants that 
practice aeration of influent water may also emit small amounts of 




Little data are available to estimate releases of isophorone to water. 
During isophorone manufacture, process water may contact the isophorone and 
carry some of it to wastewater streams. During use of isophorone, paint 
spray booths that use water curtains, wash water, and process water all may 
contain isophorone. Isophorone has been detected in the United States in 
industrial effluent discharges (Bursey and Pellizzari 1982; Hawthorne and 
Sievers 1984; Hawthorne et al. 1985; Jungclaus et al. 1976), hazardous waste 
landfill leachate and runoff (Ghassemi et al. 1984; Hauser and Bromberg 
1982; Stonebraker and Smith 1980), and urban runoff (Cole et al. 1984). 
Specific industrial categories that produce wastewaters containing 
isophorone include timber products, petroleum refining, paint and ink, pulp 
and paper, automobile and other laundries, pharmaceuticals, foundries, 
transportation equipment, and publicly-owned treatment works (Bursey and 
Pellizzari 1982). It is likely that treated waters from these industries 
that are often discharged to surface waters will contain isophorone (Bursey 




The only direct measurements of isophorone in soil were found for 
samples taken from hazardous waste sites. Ghassemi et al. (1984) found 
isophorone in leachates from hazardous waste landfills, and Hauser and 
Bromberg (1982) detected the presence of isophorone in the 
"sediment/soil/water" of Love Canal. These studies suggest that isophorone 
also was present in the soil. The Contract Laboratory Program Statistical 
Data Base (queried April 13, 1987) reported that isophorone has been 
detected at 4 of 357 hazardous waste sites at a concentration range of 1.68- 
6500 ppm. 
 
5.3 ENVIRONMENTAL FATE 
 
5.3.1 Transport and Partitioning 
 
Isophorone has a water solubility of 12,000 ppm, a log octanol/water 
partition coefficient of 1.67, a Henry's Law constant of 4.55 X 10m-6 atm m3 
mol-l, a vapor pressure of 0.3 mm Hg at 2O'C, a log sediment sorption 
coefficient of approximately 1.46, and a log bioconcentration factor (BCF) 
of 0.85. Isophorone is released to air and water from its manufacturing and 
use. Based on its water solubility, some isophorone may wash out of the 
atmosphere; however, only limited amounts will be washed out because of the 
short atmospheric half-life of isophorone. Particularly during the day, 
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when hydroxyl radical (HO·) concentrations are highest, very little
atmospheric transport will occur due to its fast reaction with HO·.
In water, neither volatilization nor sorption to sediments is expected
to be an important transport mechanism. The results of two EXAMS model runs
and the value of the Henry's Law constant (calculated from the solubility'
and the vapor pressure) suggest that volatilization will not be important in
shallow ponds or in lakes. EXAMS is an environmental model that predicts
the behavior of a chemical in surface waters (EPA 1985a). Using the code
test data for a pond developed by the Athens Environmental Research
Laboratory of EPA, the half-life for volatilization was calculated to be 104
days, while for a lake, the half-life was calculated to be 288 days. Input
data included molecular weight, vapor pressure, Henry's Law constant,
octanol/water partition coefficient, sediment sorption coefficient, and
water solubility. Equations correlating solubility or octanol/water
partition coefficients with sorption partition coefficients (Koc) were not
developed using structures similar to isophorone, however, and the Koc value
entered into the EXAMS model thus should be viewed as tentative. The
volatilization rates predicted by the EXAMS model appear to be consistent
with the observation of Hawthorne and Sievers (1984), who reported that
isophorone could be analyzed in wastewater by purge and trap methods but was
not found in the air above the wastewater in a closed system without a
purge.
McFall et al. (1985) reported isophorone concentrations in sediments of
Lake Pontchartrain, LA, an estuary located in the Mississippi River delta.
Sediments containing isophorone were detected in the Inner Harbor Navigation
Canal (IHNC), the Rigolets, and the Chef Menteur Pass. Concentrations in the
overlying waters were not reported. Therefore, the sorption partition
coefficient in these sediments could not be derived from these experimental
data.
The bioconcentration of isophorone in bluegill sunfish has been
reported by Barrows et al. (1978, 1980) and Veith et al. (1980) (all
reports used the same BCF value). These researchers reported a
bioconcentration factor of 7 (log BCF = 0.85) as determined in a continuous
dilution flow-through system using 14C-labeled isophorone. This value suggests
that concentrations of isophorone in fish living in isophorone contaminated
waters will not be more than an order of magnitude higher than concentrations
in the water. Nonetheless, concentrations of isophorone have been found in
fish in Lake Michigan tributaries and embayments (Camanzo et al. 1987) (see
section 5.4) at concentrations ranging from below the detection limit (≅0.02
mg/kg) to 3.61 mg/kg wet weight. McFall et al. (1985) also analyzed oysters
from the IHNC and clams from the Rigolets and the Chef Menteur Pass in Lake
Pontchartrain for isophorone. Oysters from the IHNC had detectable levels of
isophorone (38 ppb dry weight), but clams did not; the detection limits were
not specified and no BCF can be calculated with the data supplied. These data









correlation was found between the concentration of isophorone and lipid 
content in the organism (Camanzo et al. 1987). 
 




No studies were located regarding the rates or products of reaction of 
isophorone in the atmosphere. Isophorone does not significantly absorb light 
above wavelengths of 290 nm (Sadtler Index 1966 [UV #44]); hence, it is not 
expected to undergo direct photolysis. However isophorone can react with 
photochemically produced NOx in the atmosphere (usually formed at higher 
concentrations in photochemical smogs) producing moderate eye irritation, 
N02, other oxidants (including ozone, various peroxy compounds, and free 
radicals), and formaldehyde as indicated in smog chamber studies (Altshuller 
and Bufalini 1971; Farley 1977; Levy 1973). Probably, the most significant 
reaction of isophorone in the atmosphere is its reaction with HO.. 
Addition of HO. will occur at the double bond of the compound and may be 
followed by multiple reaction pathways (Atkinson 1985). Recently, Atkinson 
(1987) developed a method to estimate the HO· reaction rate based on 
structure.  Using this method, an overall reaction rate of 81.5 x 10-l2 cm3 
molecule-i set was calculated. This reaction rate yields a half-life of 
4.7 hours for3an atmospheric 24-hour average HO· concentration of 0.5 x l06 
molecules cm (Atkinson 1985). In indoor air, HO· concentrations probably 
are significantly lower (Atkinson 1985); therefore, reaction half-lives of 
HO· with isophorone in indoor air probably will be much longer than in 
outdoor air. Thus, isophorone is expected to persist much longer in indoor 




The aerobic biodegradation of isophorone has been studied using sludge 
and wastewater inocula as well as combined biological and physical treatment 
methods. Isophorone appears to biodegrade under most conditions simulating 
those in sewage treatment plants. No studies regarding biodegradation or 
abiotic reactions involving photolysis or oxidation of isophorone in surface 
and groundwater were located in the literature. 
 
Aerobic biodegradation of isophorone appears to be possible in sewage 
sludge or settled domestic wastewater. The exact conditions, however, 
appear to be important. For example, Tabak et al. (1981a,b) reported 100% 
degradation of isophorone in 7 days using settled domestic wastewater 
amended with 5 ppm of yeast extract. Price et al. (1974) reported that the 
equivalent of 42% theoretical oxygen demand for the compound was consumed in 
20 days with a domestic wastewater seed without the yeast extract, and 
Kawasaki (1980) reported that isophorone was resistant to biodegradation in 
a test developed by the Japanese Ministry of International Trade and 
Industry (MITI). The MIT1 test is essentially a BOD test conducted over 14 








Japan. The results are reported as a pass if 30% or more of the theoretical 
BOD is consumed and as a fail if less than 30% is consumed. During the 
operation of two model sewage treatment plants, Hannah et al. (1986) and 
McShane et al. (1987) reported that virtually all of the isophorone added to 
the influent water was removed during the activated sludge portion of the 
treatment process. The hydraulic detention times for both systems were on 
the order of several hours. None of the test concentrations were near the 
activated sludge EC50 of 100 ppm (Yoshioka et al. 1986). Some of the 
removal may have been due to adsorption to the sludge as Hannah et al. 
(1986) reported that the sludge from their process contained isophorone at 
concentrations that exceeded the influent water concentrations. 
 
While the evidence presented in the literature cited above suggests 
that isophorone can be virtually completely removed under sewage treatment 
plant conditions, monitoring data presented in Section 5.4 indicate that 
isophorone is still present in treated wastewater and in ambient water. 
This, in turn, suggests that the exact conditions under which isophorone is 
rapidly biodegraded or removed are not well understood. The presence of 
this compound in treated wastewater is indicative that the proper removal 
conditions were not employed for these systems, or that the input 
concentrations into sewage treatment plants were high enough that the 




No studies were located regarding the transformation of isophorone in 
soils. Based on the information presented above and the lack of any 
monitoring data that report isophorone in groundwater or soils (except for 
hazardous waste sites), it appears that isophorone may not be discharged to 
soils in large amounts, and the small amounts that are deposited may degrade 
rapidly in soil. Another explanation, however, is that there is a lack of 
studies determining isophorone content in soil. 
 




No ambient air monitoring for isophorone was located in the literature. 
The estimated atmospheric half-life of isophorone is <5 hours may account 
for the lack of monitoring data, since concentrations will decrease rapidly 
with distance from the source. Another explanation, however, is that no 




Isophorone has been detected in surface waters, sediments, drinking 
water, industrial effluents, urban runoff, and in runoff waters from 










In general, isophorone is found in urban centers .and appears to result 
from industrial activities, For example, its presence in the Delaware River 
near Philadelphia is the result of industrial effluents that are discharged, 
into the sewer system (Hites 1979). The sewage is treated in Philadelphia's 
Northeast Sewage Treatment plant, which discharges its effluent into the 
Delaware River. Isophorone was detected in the Delaware River in the winter 
only; in the summer, biodegradation or other processes (e.g., sorption) may 
have removed it from the water column. Isophorone has been detected in the 
sediments of Lake Pontchartrain, which is located in the delta plain of the 
Mississippi River, Its presence probably is due to the many industries that 
are situated along the.Mississippi River and use the river water as process 
water. Levels of isophorone in surface waters range from a trace to 100 ppb; 
however, this range represents only a few determinations.  
 
The presence of isophorone in drinking water is probably the result of 
using contaminated surface water as a source of drinking water. Of the 
three cities for which drinking water data are listed, Philadelphia receives 
its drinking water from the Delaware River, Cincinnati from the Ohio River, 
and New Orleans from the Mississippi River. These rivers receive numerous 
industrial effluents. 
 
As listed in Table 5-1, isophorone has been detected in the effluents 
of a variety of industries. Levels in industrial effluents range from 4.2- 
1380 ppb. Five reports of positive identifications were found in the open 
literature: a shale oil site; a tire manufacturing plant; sewer pump sample 
receiving wastes from phenolic resins manufacturing or processing, vinyl 
acetate, and polyvinylchloride process areas; final effluent from a sewage 
treatment system receiving wastes from plants producing plasticizers, butyl 
rubber, and olefin; and an unspecified effluent. The remaining samples 
listed in Table 5-l are from an EPA data base of over 4000 analyses of 
organic pollutants in industrial wastewater made during the survey conducted 
in response to the consent decree between the Natural Resources Defense 
Council and EPA, June 7, 1976 (Bursey and Pellizzari 1982). 
 
Isophorone also has been detected in urban runoff from Washington, DC 
(Cole et al. 1984). It has been detected in water (unspecified type) at 13 
of 357 hazardous waste sites as shown in the contract laboratory statistical 




Isophorone has been identified in soil only at hazardous waste sites. 
The contract laboratory program statistical data base reports that 









5.4.4 Other Media 
 
Isophorone has been detected in oysters (but not in clams) in Lake 
Pontchartrain, LA; the mean of eight samples of oysters from the Inner 
Harbor Navigation Canal section of the lake contained 38 ppb dry weight of, 
isophorone. Hall et al. (1987) and De Vault (1985) did not detect 
isophorone in the fish in the Potomac River and Great Lakes Harbors and 
tributaries, respectively; in these cases, isophorone was not detected in 
the water either. Camanzo et al. (1987) reported finding isophorone in 
nearshore fish from 14 Lake Michigan tributaries and embayments; their 
results are presented in Table 5-2. Sampling was performed in 1983. 
Isophorone was detected in fish samples from all but 2 of the sites; the 
mean of the samples that had detectable levels of the compound was 1.17 
mg/kg wet weight. In addition to isophorone, the authors also reported the 
lipid content of the composite fish samples. No correlation could be found 
between isophorone concentration and lipid content. 
 
Johansson and Ryhage (1976) reported that isophorone was present in one 
of three samples of the pharmaceutical clofibrate [ethyl 2-(4- 
chlorophenoxy)-2-methylpropionate], which lowers elevated serum lipids. The 
analysis was performed on samples available from Sweden, but clofibrate is 
also available in the United States. The concentration of isophorone 
present in samples of the drug available in the United States was not 
reported. 
 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXJ?OSURE 
 
No ambient air monitoring data are available for isophorone; 
consequently, no potential inhalation exposures from ambient air can be 
estimated. Inhalation of isophorone from showering with contaminated water 
cannot be estimated from the available data (no measurements have been 
made). 
 
Isophorone concentrations in surface waters and drinking waters are 
expected to vary considerably with season and with fluctuations in 
industrial discharges. Considering the dates of most of the positive 
identifications in surface and drinking water (middle to late 197Os), the 
effect of more stringent discharge limits in some industries since that 
time, and the probable seasonal, spatial, and temporal variations in 
concentrations, it is not possible to make an accurate estimate of 
ingestion intake of isophorone from drinking water without significant 
uncertainty. From the available data, it appears that long-term ingestion 
of isophorone from drinking water will be limited to those systems that 
receive their water from contaminated surface water sources and the 
seasonally averaged concentration in these waters probably will be <l ppb. 
 
Anjou and von Sydow (1967) reported that 0.2% of the essential oil of 
the American cranberry, Vaccinium macrocarnon, consisted of isophorone; they 










oil in whole cranberries. Without this information it is not possible to 
estimate the concentration of isophorone in whole cranberries and compare 
the concentration to other sources. However, frequent consumption of 
cranberry containing products is unlikely to represent significant intake'of 
isophorone. Ingestion of isophorone from consumption of fish and shellfish 
cannot validly be estimated from the available data (see Table 5-2). 
 
Potential dermal exposure levels also are difficult to estimate from 
the available data. Dermal exposure from bathing in contaminated waters 
cannot be estimated without significant uncertainty. Other potential dermal 
exposures cannot be estimated with the available data. 
 
Occupational exposures have been documented most frequently in the 
screen printing trade and are summarized in Table 5-3. During screen 
printing operations, both dermal and inhalation exposures can occur. 
Breathing zone concentrations during screen printing range from <l to 25.7 
ppm, while general area concentrations range from <l to 16 ppm. The 
exposure level varies significantly with the ventilation present in the work 
area. While exposure estimate for a specific screen printing operation is 
possible, no reasonable estimates can be made for other operations that may 
use isophorone because of lack of data. 
 
The relative contributions of the exposure routes and sources are as 
follows. For persons exposed to isophorone in the workplace, total doses 
will probably be substantially higher than those exposed only to ambient air 
and drinking water, and their inhalation and dermal exposures for the 
occupationally exposed can be assumed to result exclusively from the 
workplace exposures. Inhalation and dermal exposure for persons not exposed 
to isophorone in the workplace will most likely result from showering or 
bathing, but only in locations that receive their drinking water from 
contaminated surface water sources. These exposures are expected to be very 
small. In locations that do not have the potential for isophorone in the 
drinking water, any ingestion, inhalation, or dermal exposure is unlikely. 
 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURE 
 
Populations with potentially high exposure include those occupationally 
exposed to isophorone (e.g., screen print workers, some adhesives 
formulators and users, some coatings manufacturing and use workers). 
Individuals living near hazardous waste sites may be exposed to isophorone 
dermally, but probably not by inhalation. These individuals also may be 
exposed to isophorone by ingestion if they drink water from contaminated 
wells located down gradient from the site. 
 
5.7 ADEQUAGY OF THE DATABASE 
 
Section 104 (i) (5) of CERCLA, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the 









effects of isophorone is available. Where adequate information is not 
available, ATSDR, in cooperation with the National Toxicology Program (NTP), 
is required to assure the initiation of a program of research designed to 
determine these health effects (and techniques for developing methods to 
determine such health effects). The following discussion highlights the 
availability, or absence, of exposure and toxicity information applicable to 
human health assessment. A statement of the relevance of identified data 
needs is also included. In a separate effort, ATSDR, in collaboration with 
NTP and EPA, will prioritize data needs across chemicals that have been 
profiled. 
 
5.7.1 Data Needs 
 
Physical and Chemical Properties. Physical and chemical properties are 
essential for estimating the partitioning of a chemical in the environment. 
Many physical and chemical properties are available for isophorone, but most 
do not have extensive experimental descriptions accompanying the data; 
therefore, an evaluation of the accuracy of the data is difficult. 
Specifically, measured vapor pressure, KOC, and Henry's Law constant at 
environmentally significant temperatures would help to remove doubt 
regarding the accuracy of the estimated data. The data on physical 
properties form the basis of much of the input requirements for 
environmental models that predict the behavior of a chemical under specific 
conditions, including hazardous waste landfills. The data on the chemical 
properties, on the other hand, can be useful in predicting certain 
environmental fates of this chemical. 
 
Environmental Fate. Sensitized photolysis studies in water and 
oxidation/reduction studies in both air and water are lacking, as are 
biodegradation studies in surface and groundwaters. These kinds of studies 
are important, since they represent the fundamental removal mechanisms 
available to isophorone in the environment. In addition, the kinetic 
studies for the atmospheric reactions are important for understanding the 
significance of a removal mechanism and predicting the reactions that may 
control the fate of a chemical in the environment. 
 
Exposure Levels in Environmental Media. Environmental monitoring data 
are not available for soil and air, and the data available for water, 
sediments, and biota are not sufficient to determine ambient 
concentrations. These data would be helpful in determining the ambient 
concentrations of isophorone so that exposure estimates of the general 
population and the bioconcentration factor of this chemical in aquatic 
organisms can be made. 
 
Exposure Levels in Humans. No information is available concerning 
exposure levels of isophorone in humans. A data base would be helpful in 
determining the current exposure levels, and thereby allowing an estimation 
of the average daily dose associated with various sources (e.g., living near 








program involving analyses of human tissues would be useful in assessing the 
magnitude of environmental exposures. Monitoring of human tissues from 
different locations and seasons and using different category of the 
population would be helpful so that the effects of such variables as 
occupational, geographical, and seasonal can be assessed. 
 
Exposure Registries. An exposure registry (e.g., for occupationally 
exposed groups) currently is not available. The development of a registry 
of exposures would provide a useful reference tool in assessing exposure 
levels and frequencies. In addition, a registry developed on the basis of 
exposure sources would allow an assessment of the variations in exposure 
levels from one source to another and the effect of geographical, seasonal, 
regulatory actions on the level of exposure within a certain source. These 
assessments, in turn, would provide a better understanding of the needs for 
research or data acquisition based on the current exposure levels. 
 
5.7.2 On-going Studies 
 









6.1 BIOLOGICAL MATERIALS 
 
No study was located regarding the analysis of isophorone in human 
biological materials, but animal studies (see Section 2.6) suggest that 
methods are available. In general, isophorone was extracted from the urine 
using ether (continuous extraction for 48 hours) followed by evaporation of 
the ether (Dutertre-Catella et al. 1978; Truhaut et al. 1970). The 
resulting residue was subjected to gas chromatography with flame ionization 
detector using the retention time as the indicator for the presence of 
isophorone or metabolites. In distribution studies, isophorone was 
extracted from minced tissues with dichloromethane, and the extract was 
analyzed by gas chromatography using the flame ionization detector 
(Dutertre-Catella 1976). In addition to these methods for analyzing 
isophorone in mammalian urine and tissues, Ozretich and Schroeder (1986) 
described a method for analyzing isophorone in fish tissue (Table 6-l). 
 
6.2 ENVIRONMENTAL SAMPLES 
 
Isophorone can be analyzed in municipal and industrial wastewater by 
EPA Test Method 609 - Nitroaromatics and Isophorone, or by EPA Test Method 
625 Base/Neutrals and Acids (EPA 1982; Shafer 1982). These methods are 
adequate for measuring isophorone in most wastewaters, although interfering 
compounds may be present in some wastewaters. Method 609 involves the 
extraction of isophorone with methylene chloride followed by solvent 
exchange to hexane and analysis by gas chromatography (GC) using a flame 
ionization detector (FID). Method 625 is similar to Method 609, but the 
extraction is performed at pH 11 and is followed by concentration (without 
solvent exchange) and GC/MS analysis. The Contract Laboratory Procedure 
(EPA 1987a) is essentially identical (Table 6-l). The average recovery from 
reagent water and effluents was 49-67% for Method 609 and 75 ± 33% from 
reagent water for method 625, Method 609 shows a pronounced negative bias 
(the concentration detected by the method is lower than the true 
concentration present) (Kinzer et al. 1984). Table 6-l presents accuracy 
and detection limit data for the methods. In air, isophorone can be analyzed 
by NIOSH Method 2508 (NIOSH 1984). The method involves drawing a 2 to 25 
liter air sample through a petroleum based charcoal tube followed by carbon 
disulfide desorption and analysis by GC-FID. The method has a range of 0.2- 
10 mg per tube and a detection limit of 0.02 mg per tube. Table 6-l 
presents accuracy information for this method. 
 
The method for analyzing soil in the EPA Contract Laboratory Program 
involves the extraction of isophorone using methylene chloride followed by 
analysis by GC/MS. The usual detection limit is 330 ppb, although the exact 









6.3 ADEQUACY OF THE DATABASE 
 
Section 104 (i) (5) of CERCLA, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the 
Public Health Service) to assess whether adequate information on the health 
effects of isophorone is available. Where adequate information is not 
available, ATSDR, in cooperation with the National Toxicology Program (NTP), 
is required to assure the initiation of a program of research designed to 
determine these health effects (and techniques for developing methods to 
determine such health effects). The following discussion highlights the 
availability, or absence, of exposure and toxicity information applicable to 
human health assessment. A statement of the relevance of identified data 
needs is also included. In a separate effort, ATSDR, in collaboration with 
NTP and EPA, will prioritize data needs across chemicals that have been 
profiled. 
 
6.3.1 Data Needs 
 
Methods for Parent Compound and Metabolites in Biological Materials. 
No information is available concerning the analysis of isophorone in 
biological materials. If information were available, it would allow both 
investigators and reviewers to assess the accuracy and uncertainty of the 
methods used. Furthermore, the ready availability of tested analytical 
methods would permit a standardized approach to the analysis of biological 
materials and allow a comparison of the levels of exposure with the possible 
health effects in humans. 
Methods for Biomarkers of Exposure. No methods are available for the 
analysis of isophorone biomarkers of exposure in biological materials. If a 
method for the determination of the level of a specific biomarker were 
available in a biological medium, it could be used to indicate the level of 
exposure and the possible resultant health effect. 
 
Methods for Parent Compound and Degradation Products in Environmental 
Media. Adequate methods appear to be available for the analysis of isophorone 
in groundwater, surface water, soil, and workplace air. No methods were found 
for the analysis of isophorone in ambient air, where concentrations are 
expected to be much lower than in workplace air. If the parent compound is 
stable as in the present case, it is essential that its concentrations in 
different environmental media be known so that the level of its exposure can 
be estimated. 
 
No adequate methods appear to be available for the analysis of 
isophorone degradation products in environmental media. In cases where a 
degradation product of a chemical is toxic, it is important that its 
concentration in the environment be known. In certain instances, monitoring 
the level of a degradation product may be used as an indirect measurement of 








6.3.2 On-going Studies 
 
No studies were located regarding on-going analytical methods 
development for isophorone. 
83
7 . REGULATIONS AND ADVISORIES
International guidelines for isophorone were not located. National and
state regulations and guidelines.pertinent to human exposure to isophorone
are summarized in Table 7-1.
Isophorone is regulated by the Clean Water Effluent Guidelines for the
following industrial point sources: electroplating, steam electric,
asbestos manufacturing, timber products processing, metal finishing, paving
and roofing, paint formulating, ink formulating, gum and wood, carbon black,
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Acute Exposure -- Exposure to a chemical for a duration of 14 days or less, 
as specified in the Toxicological Profiles. 
 
Adsorption Coefficient (Koc) -- The ratio of the amount of a chemical 
adsorbed per unit weight of organic carbon in the soil or sediment to the 
concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or 
soil (i.e., the solid phase) divided by the amount of chemical in the 
solution phase, which is in equilibrium with the solid phase, at a fixed 
solid/solution ratio. It is generally expressed in micrograms of chemical 
sorbed per gram of soil or sediment. 
 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a 
chemical in aquatic organisms at a specific time or during a discrete time 
period of exposure divided by the concentration in the surrounding water at 
the same time or during the same time period. 
 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study or group 
of studies which produces significant increases in incidence of cancer (or 
tumors) between the exposed populaton and its appropriate control. 
 
Carcinogen -- A chemical capable of inducing cancer. 
 
Ceiling Value (CL) -- A concentration of a substance that should not be 
exceeded, even instantaneously. 
 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as 
specified in the Toxicological Profiles. 
 
Developmental Toxicity -- The occurrence of adverse effects on the 
developing organism that may result from exposure to a chemical prior to 
conception (either parent), during prenatal development, or postnatally to 
the time of sexual maturation. Adverse developmental effects may be detected 
at any point in the life span of the organism. 
 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a 
result of prenatal exposure to a chemical; the distinguishing feature 
between the two terms is the stage of development during which the insult 
occurred. The terms, as used here, include malformations and variations, 
altered growth, and in utero death. 
 
EPA Health Advisory -- An estimate of acceptable drinking water levels for a 
chemical substance based on health effects information. A health advisory is 
not a legally enforceable federal standard, but serves as technical guidance 








Immediately Dangerous to Life or Health (IDIX) -- The maximum environmental 
concentration of a contaminant from which one could escape within 30 min 
without any escape-impairing symptoms or irreversible health effects. 
 
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 
days, as specified in the Toxicological Profiles. 
 
Immunologic Toxicity -- The occurrence of adverse effects on the immune 
system that may result from exposure to environmental agents such as 
chemicals. 
 
In vitro -- Isolated from the living organism and artificially maintained, 
as in a test tube. 
 
In vivo -- Occurring within the living organism. 
 
Lethal Concentration(L0) (LCLO) -- The lowest concentration of a chemical in 
air which has been reported to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50) -- A calculated concentration of a chemical 
in air to which exposure for a specific length of time is expected to cause 
death in 50% of a defined experimental animal population. 
 
Lethal Dose(50) (LDLO) -- The lowest dose of a chemical introduced by a 
route other than inhalation that is expected to have caused death in humans 
or animals. 
 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated 
to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical 
in a study or group of studies which produces statistically or biologically 
significant increases in frequency or severity of adverse effects between 
the exposed population and its appropriate control. 
 
LT50 (lethal time) -- A calculated period of time within which a specific 
concentration of a chemical is expected to cause death in 50% of a defined 
experimental animal population. 
 
Malformations -- Permanent structural changes that may adversely affect 
survival, development, or function. 
 
Minimal Risk Level -- An estimate of daily human exposure to a chemical that 
is likely to be without an appreciable risk of deleterious effects 









Mutagen -- A substance that causes mutations. A mutation is a change in the 
genetic material in a body cell. Mutations can lead to birth defects, 
miscarriages, or cancer. 
 
Neurotoxicity -- The occurrence of adverse effects on the nervous system 
following exposure to a chemical. 
 
No-Observed-Adverse-Effect Level (NOAEL) -- That dose of chemical at which 
there are no statistically or biologically significant increases in 
frequency or severity of adverse effects seen between the exposed 
population and its appropriate control. Effects may be produced at this 
dose, but they are not considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow) -- The equilibrium ratio of the 
concentrations of a chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace 
air averaged over an 8-h shift. 
 
q*1 -- The upper-bound estimate of the low-dose slope of the dose-response 
curve as determined by the multistage procedure. The ql* can be used to 
calculate an estimate of carcinogenic potency, the incremental excess cancer 
risk per unit of exposure (usually g/L for water, mg/kg/day for food, and 
g/m3 for air). 
 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an 
order of magnitude) of the daily exposure of the human population to a 
potential hazard that is likely to be without risk of deleterious effects 
during a lifetime. The RFD is operationally derived from the NOAEL (from 
animal and human studies) by a consistent application of uncertainty factors 
that reflect various types of data used to estimate RfDs and an additional 
modifying factor, which is based on a professional judgment of the entire 
database on the chemical. The RfDs are not applicable to nonthreshold 
effects such as cancer. 
 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that is 
considered reportable under CERCLA. Reportable quantities are: (1) 1 lb or 
greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities 
are measured over a 24-h period. 
 
Reproductive Toxicity -- The occurrence of adverse effects on the 
reproductive system that may result from exposure to a chemical. The 
toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as 
alterations in sexual behavior, fertility, pregnancy outcomes, or 










Short-Term Exposure Limit (STEL) -- The maximum concentration to which 
workers can be exposed for up to 15 min continually. No more than four 
excursions are allowed per day, and there must be at least 60 min between 
exposure periods. The daily TLV-TWA may not be exceeded. 
 
Target Organ Toxicity -- This term-covers a broad range of adverse effects 
on target organs or physiological systems (e.g., renal, cardiovascular) 
extending from those arising through a single limited exposure to those 
assumed over a lifetime of exposure to a chemical. 
 
TD50 (toxic dose) -- A calculated dose of a chemical, introduced by a route 
other than inhalation, which is expected to cause a specific toxic effect in 
50% of a defined experimental animal population. 
 
Teratogen -- A chemical that causes structural defects that affect the 
development of an organism. 
 
Threshold Limit Value (TLV) -- A concentration of a substance to which most 
workers can be exposed without adverse effect. The TLV may be expressed as a 
TWA, as a STEL, or as a CL. 
 
Time-weighted Average (TWA) -- An allowable exposure concentration averaged 
over a normal 8-h workday or 40-h workweek. 
 
Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD 
from experimental data. UFs are intended to account for (1) the variation in 
sensitivity among the members of the human population, (2) the uncertainty 
in extrapolating animal data to the case of humans, (3) the uncertainty in 
extrapolating from data obtained in a study that is of less than lifetime 
exposure, and (4) the uncertainty in using LOAEL data rather than NOAEL 








A peer review panel was assembled for isophorone. The panel consisted 
of the following members: Dr. Rip G. Rice, Private Consultant, Rice 
Incorporated, Ashton, MD; Dr. Anthony P. DeCaprio, Private Consultant, 
Albany, NY; Dr. Bhola N. Banerjee, Private Consultant, Potomac, MD; and Dr. 
Judith S. Bellin, Private Consultant, Washington, DC These experts 
collectively have knowledge of isophorone's physical and chemical 
properties, toxicokinetics, key health end points, mechanisms of action, 
human and animal exposure, and quantification of risk to humans. All 
reviewers were selected in conformity with the conditions for peer review 
specified in the Superfund Amendments and Reauthorization Act of 1986, 
Section 110. 
 
A joint panel of scientists from ATSDR and EPA has reviewed the peer 
reviewers' comments and determined which comments will be included in the 
profile. A listing of the peer reviewers' comments not incorporated in the 
profile, with a brief explanation of the rationale for their exclusion, 
exists as part of the administrative record for this compound. A list of 
databases reviewed and a list of unpublished documents cited are also 
included in the administrative record. 
 
The citation of the peer review panel should not be understood to 
imply their approval of the profile's final content. The responsibility for 
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